<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02257567</url>
  </required_header>
  <id_info>
    <org_study_id>GO29365</org_study_id>
    <secondary_id>2014-001361-28</secondary_id>
    <nct_id>NCT02257567</nct_id>
  </id_info>
  <brief_title>A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma</brief_title>
  <official_title>A Phase IB/II Study Evaluating The Safety, Tolerability and Anti-Tumor Activity of Polatuzumab Vedotin in Combination With Rituximab (R) or Obinutuzumab (G) Plus Bendamustine (B) in Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hoffmann-La Roche</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multicenter, open-label study of polatuzumab vedotin administered by&#xD;
      intravenous (IV) infusion in combination with standard doses of bendamustine (B) and&#xD;
      rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular&#xD;
      lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a&#xD;
      Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18&#xD;
      weeks for participants with DLBCL and 24 weeks for participants with FL.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2014</start_date>
  <completion_date type="Actual">October 21, 2021</completion_date>
  <primary_completion_date type="Actual">October 21, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Phase Ib: Percentage of Participants With Adverse Events (AEs)</measure>
    <time_frame>From the study start up to the end of the study (up to approximately 84 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs</measure>
    <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin</measure>
    <time_frame>Baseline up to approximately Month 24</time_frame>
    <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</measure>
    <time_frame>Baseline up to approximately Month 24</time_frame>
    <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
    <description>The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</measure>
    <time_frame>6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms*day per milliliters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With AEs</measure>
    <time_frame>From the study start up to the end of the study (up to approximately 84 months)</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin</measure>
    <time_frame>Baseline to approximately Month 24</time_frame>
    <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</measure>
    <time_frame>Baseline to approximately Month 24</time_frame>
    <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)</time_frame>
    <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC</measure>
    <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)</time_frame>
    <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)</time_frame>
    <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC</measure>
    <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)</time_frame>
    <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)</time_frame>
    <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC</measure>
    <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)</time_frame>
    <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately&gt;liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC</measure>
    <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC</measure>
    <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator</measure>
    <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC</measure>
    <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
    <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator</measure>
    <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
    <description>EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II NF Cohorts: Overall Survival (OS)</measure>
    <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
    <description>OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
    <description>CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</measure>
    <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)</time_frame>
    <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</measure>
    <time_frame>Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
    <description>PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</measure>
    <time_frame>Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose</time_frame>
    <description>PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab</measure>
    <time_frame>Cycle 1 Days 2: pre-dose &amp; 30 min post dose; Cycle 1 Days 8 &amp; 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose &amp; 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 &amp; 24; study treatment completion visit (up to approx. 84 months)</time_frame>
    <description>PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab</measure>
    <time_frame>Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose</time_frame>
    <description>PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</measure>
    <time_frame>Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
    <description>PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</measure>
    <time_frame>Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose</time_frame>
    <description>PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration of Bendamustine</measure>
    <time_frame>Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose</time_frame>
    <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Rituximab</measure>
    <time_frame>Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)</time_frame>
    <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum Concentration of Obinutuzumab</measure>
    <time_frame>Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
    <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</measure>
    <time_frame>Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</measure>
    <time_frame>Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</measure>
    <time_frame>Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Cmax of Bendamustine and Rituximab in Arms B and D</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F</measure>
    <time_frame>Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day*micrograms per milliliter [day*ug/mL]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: CL of Bendamustine and Rituximab in Arms B and D</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Vss of Bendamustine and Rituximab in Arms B and D</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</measure>
    <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)</measure>
    <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
    <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F</measure>
    <time_frame>Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)</time_frame>
    <description>The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Actual">331</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendamustine</intervention_name>
    <description>Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>Treanda; Ribomustin; Levact</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Obinutuzumab</intervention_name>
    <description>Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>GA101; Gazyva; Gazyvaro</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin (Liquid)</intervention_name>
    <description>Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm E (Phase II Expansion): Polatuzumab+BG in FL</arm_group_label>
    <arm_group_label>Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL</arm_group_label>
    <other_name>DCDS4501A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).</description>
    <arm_group_label>Arm A (Phase II Randomization): Polatuzumab+BR in FL</arm_group_label>
    <arm_group_label>Arm B (Phase II Randomization): BR in FL</arm_group_label>
    <arm_group_label>Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm D (Phase II Randomization): BR in DLBCL</arm_group_label>
    <arm_group_label>Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL</arm_group_label>
    <other_name>Rituxan; MabThera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Polatuzumab vedotin (Lyophilized)</intervention_name>
    <description>Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).</description>
    <arm_group_label>Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <arm_group_label>Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL</arm_group_label>
    <other_name>DCDS4501S</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed relapsed or refractory FL (Grades 1, 2, or 3a) or relapsed or&#xD;
             refractory DLBCL&#xD;
&#xD;
          -  If the participant has received prior bendamustine, response duration must have been&#xD;
             greater than (&gt;) 1 year (for participants who have relapse disease after a prior&#xD;
             regimen)&#xD;
&#xD;
          -  At least one bi-dimensionally measurable lesion on imaging scan defined as &gt;1.5&#xD;
             centimeters (cm) in its longest dimension&#xD;
&#xD;
          -  Confirmed availability of archival or freshly collected tumor tissue&#xD;
&#xD;
          -  The Phase II NF Cohorts (Arms G and H) will be required to submit tissue and pathology&#xD;
             report for central pathology review.&#xD;
&#xD;
          -  Life expectancy of at least 24 weeks&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2&#xD;
&#xD;
          -  Adequate hematological function unless inadequate function is due to underlying&#xD;
             disease&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to humanized or murine monoclonal&#xD;
             antibodies (MAbs, or recombinant antibody-related fusion proteins) or known&#xD;
             sensitivity or allergy to murine products&#xD;
&#xD;
          -  Contraindication to bendamustine, rituximab, or obinutuzumab&#xD;
&#xD;
          -  Prior use of any MAb, radioimmunoconjugate, or antibody-drug conjugate (ADC) within 4&#xD;
             weeks or 5 half-lives before Cycle 1 Day 1&#xD;
&#xD;
          -  Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy,&#xD;
             or any investigational agent for the purposes of treating cancer within 2 weeks prior&#xD;
             to Cycle 1 Day 1&#xD;
&#xD;
          -  Ongoing corticosteroid use &gt;30 mg per day prednisone or equivalent, for purposes other&#xD;
             than lymphoma symptom control&#xD;
&#xD;
          -  Completion of autologous stem cell transplant (SCT) within 100 days prior to Cycle 1&#xD;
             Day 1&#xD;
&#xD;
          -  Prior allogeneic SCT&#xD;
&#xD;
          -  Eligibility for autologous SCT&#xD;
&#xD;
          -  Grade 3b FL&#xD;
&#xD;
          -  History of transformation of indolent disease to DLBCL&#xD;
&#xD;
          -  Primary or secondary CNS lymphoma&#xD;
&#xD;
          -  Current Grade &gt;1 peripheral neuropathy&#xD;
&#xD;
          -  Evidence of significant, uncontrolled concomitant diseases that could affect&#xD;
             compliance with the protocol or interpretation of results, including significant&#xD;
             cardiovascular disease (such as New York Heart Association Class III or IV cardiac&#xD;
             disease, myocardial infarction within the last 6 months, unstable arrhythmias, or&#xD;
             unstable angina) or significant pulmonary disease (including obstructive pulmonary&#xD;
             disease and history of bronchospasm)&#xD;
&#xD;
          -  Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection&#xD;
             (excluding fungal infections of nail beds) at study enrollment or any major episode of&#xD;
             infection requiring treatment with IV antibiotics or hospitalization within 4 weeks&#xD;
             prior to Cycle 1 Day 1&#xD;
&#xD;
          -  Suspected or latent tuberculosis&#xD;
&#xD;
          -  Positive test results for chronic hepatitis B virus (HBV) infection or for hepatitis C&#xD;
             virus (HCV) antibody&#xD;
&#xD;
          -  Known history of human immunodeficiency virus (HIV) seropositive status or known&#xD;
             infection with human T-cell leukemia virus 1 (HTLV-1) virus&#xD;
&#xD;
          -  Women who are pregnant or lactating or who intend to become pregnant within a year of&#xD;
             the last dose of study treatment in the rituximab cohort or within 18 months of last&#xD;
             dose in the obinutuzumab cohort&#xD;
&#xD;
          -  Evidence of laboratory abnormalities in standard renal, hepatic, or coagulation&#xD;
             function tests&#xD;
&#xD;
          -  Treatment with chimeric antigen receptor T-cell therapy within 100 days prior to Cycle&#xD;
             1, Day 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>Hoffmann-La Roche</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clearview Cancer Institute</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Univ of Colorado Canc Ctr</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists; North Florida ;Jacksonville (AC Skinner Pkwy)</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Univ Winship Cancer Inst</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology; Associates, Ltd.</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology Research, Inc.</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weinberg CA Inst Franklin Sq</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21237</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Cancer Care Associates LLC - Morristown</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico Cancer Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Clinic</name>
      <address>
        <city>Germantown</city>
        <state>Tennessee</state>
        <zip>38138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Cancer Inst.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Medical Specialties</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital; Oncology</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Adelaide Hospital</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Adelaide Cancer Centre</name>
      <address>
        <city>Kurralta Park</city>
        <state>South Australia</state>
        <zip>5037</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monash Medical Centre; Haematology Research</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <zip>3168</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BCCA-Vancouver Cancer Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 4E6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II Health Sciences Centre; Oncology</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 2Y9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Maisonneuve- Rosemont; Oncology</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jewish General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1E2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Brno; Interni hematologicka a onkologicka klinika</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultni nemocnice Hradec Kralove</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fakultní nemocnice Ostrava Klinika hematoonkologie</name>
      <address>
        <city>Ostrava</city>
        <zip>70852</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>I Interni klinika; Vseobecna fakultni nemocnice</name>
      <address>
        <city>Prague 2</city>
        <zip>128 08</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chu Site Du Bocage;Hematologie Clinique</name>
      <address>
        <city>Dijon</city>
        <zip>21079</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Departemental Les Oudairies</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Leon Berard; Departement Oncologie Medicale</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Saint Eloi; Service d'Hématologie Clinique</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Lyon Sud - Service Hématologie</name>
      <address>
        <city>Pierre Benite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel; Hematologie</name>
      <address>
        <city>Rouen</city>
        <zip>76038</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Erfurt - Innere Medizin - 4. Medizinische Klinik, Hämatologie</name>
      <address>
        <city>Erfurt</city>
        <zip>99089</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin der Johannes Gutenberg-Universität Mainz, Abt. für Hämatologie und Onkologie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joh. Wesling Klinikum Minden; Klinik fuer Hämatologie und Onkologie</name>
      <address>
        <city>Minden</city>
        <zip>32429</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Hämatologie und Onkologie</name>
      <address>
        <city>Münster</city>
        <zip>48153</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik der Uni Regensburg; Hämatologie/Onkologie, Studienzentrale</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University, First Dept of Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Institute of Oncology, A Dept of Internal Medicine</name>
      <address>
        <city>Budapest</city>
        <zip>1122</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Debrecen Medical and Health Science Center, Institute of Internal medicine Building B</name>
      <address>
        <city>Debrecen</city>
        <zip>4032</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Irccs Fondazione g. Pascale;s.c. Ematologia Oncologica</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>A.O. Spedali Civili Di Brescia-P.O. Spedali Civili;U.O. Ematologia</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Irccs Istituto Europeo Di Oncologia (IEO); Emato-Oncologia</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile SS. Antonio E Biagio DI Alessandria; Ematologia</name>
      <address>
        <city>Alessandria</city>
        <state>Piemonte</state>
        <zip>15121</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC St. Radboud; Hematology</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron; Servicio de Hematologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona; Hematology</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario la Paz; Servicio de Hematologia</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Salamanca;Servicio de Hematologia</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocio; Servicio de Hematologia</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ankara University; Hematology</name>
      <address>
        <city>Ankara</city>
        <zip>06620</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dokuz Eylul Uni ; Hematology</name>
      <address>
        <city>Izmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ondokuzmayis University Medical Faculty Heamatology Department</name>
      <address>
        <city>Samsun</city>
        <zip>55139</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karadeniz Technical Uni School of Medicine; Hematology</name>
      <address>
        <city>Trabzon</city>
        <zip>61800</zip>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KINGS COLLEGE HOSPITAL; Commercial R&amp;D Amendments, Kings Health Partners Clinical Trials Office</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christie Hospital Nhs Trust; Medical Oncology</name>
      <address>
        <city>Manchester</city>
        <zip>M2O 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nottingham City Hospital; Dept of Haematology</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton General Hospital; Somers Cancer Research Building</name>
      <address>
        <city>Southampton</city>
        <zip>SO16 6YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Czechia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>Turkey</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
  </removed_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 2, 2014</study_first_submitted>
  <study_first_submitted_qc>October 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2014</study_first_posted>
  <results_first_submitted>October 18, 2022</results_first_submitted>
  <results_first_submitted_qc>October 18, 2022</results_first_submitted_qc>
  <results_first_posted type="Actual">November 14, 2022</results_first_posted>
  <last_update_submitted>October 18, 2022</last_update_submitted>
  <last_update_submitted_qc>October 18, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Obinutuzumab</mesh_term>
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Polatuzumab vedotin</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 23, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT02257567/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 331 participants with relapsed or refractory (R/R) follicular lymphoma (FL) or diffuse large B cell lymphoma (DLBCL) were enrolled in this study at 56 investigative sites in the following countries: Australia, Canada, Czech Republic, France, Germany, Hungary, Italy, Korea, the Netherlands, Spain, Turkey, United Kingdom, and the United States from 15 October 2014 to 21 October 2021.</recruitment_details>
      <pre_assignment_details>Participants were enrolled in Phase Ib and Phase II to receive polatuzumab vedotin (pola) (liquid formulation in randomized &amp; expansion stages; lyophilized formulation in new formulation (NF) cohorts) in combination with standard doses of bendamustine (B) &amp; rituximab (R)/obinutuzumab (G). Out of 331 participants, 327 participants received at least one dose of study drug and their intended treatment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 milligrams per kilogram (mg/kg), as intravenous (IV) infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 milligrams per meter-squared (mg/m^2), as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="P2">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="P3">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="P4">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="P5">
          <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="P6">
          <title>Arm B (Phase II Randomization): BR in FL</title>
          <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="P7">
          <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="P8">
          <title>Arm D (Phase II Randomization): BR in DLBCL</title>
          <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="P9">
          <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="P10">
          <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="P11">
          <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="39"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="40"/>
                <participants group_id="P8" count="40"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="21"/>
                <participants group_id="P11" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="38"/>
                <participants group_id="P6" count="41"/>
                <participants group_id="P7" count="39"/>
                <participants group_id="P8" count="39"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="20"/>
                <participants group_id="P6" count="22"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="16"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="19"/>
                <participants group_id="P6" count="19"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="38"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="21"/>
                <participants group_id="P11" count="76"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="15"/>
                <participants group_id="P6" count="11"/>
                <participants group_id="P7" count="26"/>
                <participants group_id="P8" count="30"/>
                <participants group_id="P9" count="2"/>
                <participants group_id="P10" count="18"/>
                <participants group_id="P11" count="65"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="2"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not treated/Per Sponsor Participant Could not Continue/Pathology Showed Transformation: Cycle 1Day 1</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="2"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="2"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="6"/>
                <participants group_id="P8" count="6"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="1"/>
                <participants group_id="P11" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-treat (ITT) population included all participants who were randomized, whether or not the participants received the assigned treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="B2">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="B3">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="B4">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="B5">
          <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="B6">
          <title>Arm B (Phase II Randomization): BR in FL</title>
          <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="B7">
          <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="B8">
          <title>Arm D (Phase II Randomization): BR in DLBCL</title>
          <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="B9">
          <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="B10">
          <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="B11">
          <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="6"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="39"/>
            <count group_id="B6" value="41"/>
            <count group_id="B7" value="40"/>
            <count group_id="B8" value="40"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="21"/>
            <count group_id="B11" value="106"/>
            <count group_id="B12" value="331"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68.0" lower_limit="54" upper_limit="73"/>
                    <measurement group_id="B2" value="65.0" lower_limit="58" upper_limit="79"/>
                    <measurement group_id="B3" value="63.5" lower_limit="42" upper_limit="73"/>
                    <measurement group_id="B4" value="71.0" lower_limit="53" upper_limit="84"/>
                    <measurement group_id="B5" value="65.0" lower_limit="37" upper_limit="74"/>
                    <measurement group_id="B6" value="63.0" lower_limit="39" upper_limit="80"/>
                    <measurement group_id="B7" value="67.0" lower_limit="33" upper_limit="86"/>
                    <measurement group_id="B8" value="71.0" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="B9" value="60.5" lower_limit="37" upper_limit="86"/>
                    <measurement group_id="B10" value="65.0" lower_limit="26" upper_limit="86"/>
                    <measurement group_id="B11" value="70.0" lower_limit="24" upper_limit="94"/>
                    <measurement group_id="B12" value="67.0" lower_limit="24" upper_limit="94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="18"/>
                    <measurement group_id="B6" value="23"/>
                    <measurement group_id="B7" value="12"/>
                    <measurement group_id="B8" value="15"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="10"/>
                    <measurement group_id="B11" value="54"/>
                    <measurement group_id="B12" value="151"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="21"/>
                    <measurement group_id="B6" value="18"/>
                    <measurement group_id="B7" value="28"/>
                    <measurement group_id="B8" value="25"/>
                    <measurement group_id="B9" value="10"/>
                    <measurement group_id="B10" value="11"/>
                    <measurement group_id="B11" value="52"/>
                    <measurement group_id="B12" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="8"/>
                    <measurement group_id="B12" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="2"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="33"/>
                    <measurement group_id="B6" value="33"/>
                    <measurement group_id="B7" value="26"/>
                    <measurement group_id="B8" value="31"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="15"/>
                    <measurement group_id="B11" value="83"/>
                    <measurement group_id="B12" value="259"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="5"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="14"/>
                    <measurement group_id="B12" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="3"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="34"/>
                    <measurement group_id="B6" value="34"/>
                    <measurement group_id="B7" value="35"/>
                    <measurement group_id="B8" value="36"/>
                    <measurement group_id="B9" value="16"/>
                    <measurement group_id="B10" value="19"/>
                    <measurement group_id="B11" value="87"/>
                    <measurement group_id="B12" value="285"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Stated</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="3"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="3"/>
                    <measurement group_id="B12" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Phase Ib: Percentage of Participants With Adverse Events (AEs)</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).</description>
        <time_frame>From the study start up to the end of the study (up to approximately 84 months)</time_frame>
        <population>Safety population consisted of all ITT participants from Phase Ib who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Percentage of Participants With Adverse Events (AEs)</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).</description>
          <population>Safety population consisted of all ITT participants from Phase Ib who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
        <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
        <population>Safety population consisted of all ITT participants from Arms G+H (Phase II NF Cohort) who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Arms G+H (Phase II NF Cohort) who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin</title>
        <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
        <time_frame>Baseline up to approximately Month 24</time_frame>
        <population>Safety population consisted of all ITT participants from Cohort 1a (Phase Ib) who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin</title>
          <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Cohort 1a (Phase Ib) who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Prevalence of ADAs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.0"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="33.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</title>
        <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
        <time_frame>Baseline up to approximately Month 24</time_frame>
        <population>Safety population consisted of all ITT participants from Cohort 1b (Phase Ib) who received at least one dose of study medication. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</title>
          <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Cohort 1b (Phase Ib) who received at least one dose of study medication. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Prevalence of ADAs to Polatuzumab vedotin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs to Polatuzumab vedotin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Prevalence of ADAs to Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADA to Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)</title>
        <description>The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
        <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
        <population>Safety population consisted of all ITT participants from Arm G+H (Phase II NF cohort) who received at least one dose of study medication. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)</title>
          <description>The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Arm G+H (Phase II NF cohort) who received at least one dose of study medication. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
                <count group_id="O2" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Prevalence of ADAs to Polatuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="41"/>
                    <count group_id="O2" value="62"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs to Polatuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="39"/>
                    <count group_id="O2" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6"/>
                    <measurement group_id="O2" value="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)</title>
        <description>CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II Randomized and NF cohorts irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)</title>
          <description>CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II Randomized and NF cohorts irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.2" lower_limit="52.43" upper_limit="82.98"/>
                    <measurement group_id="O2" value="63.4" lower_limit="46.94" upper_limit="77.88"/>
                    <measurement group_id="O3" value="42.5" lower_limit="27.04" upper_limit="59.11"/>
                    <measurement group_id="O4" value="17.5" lower_limit="7.34" upper_limit="32.78"/>
                    <measurement group_id="O5" value="39.6" lower_limit="30.25" upper_limit="49.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5353</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>5.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.53</ci_lower_limit>
            <ci_upper_limit>25.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0128</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates (4.89</param_type>
            <param_value>25.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.89</ci_lower_limit>
            <ci_upper_limit>42.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
        <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm H (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
          <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Arm H (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.2" lower_limit="29.94" upper_limit="55.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)</title>
        <description>Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms*day per milliliters.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>PK population included all ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)</title>
          <description>Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms*day per milliliters.</description>
          <population>PK population included all ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
          <units>ng*day/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2880" spread="0.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Antibody (Ab)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.6" spread="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>PK evaluable population included all the ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at the specified time point.</population>
          <units>nanograms per milliliters (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.01" spread="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this outcome measure (OM) was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)</description>
          <population>As pre-specified in the protocol the analysis of this outcome measure (OM) was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With AEs</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
        <time_frame>From the study start up to the end of the study (up to approximately 84 months)</time_frame>
        <population>Safety population consisted of all ITT participants from Phase II who received at least one dose of study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With AEs</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Phase II who received at least one dose of study medication.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="39"/>
                <count group_id="O4" value="39"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="100"/>
                    <measurement group_id="O4" value="97.4"/>
                    <measurement group_id="O5" value="100"/>
                    <measurement group_id="O6" value="100"/>
                    <measurement group_id="O7" value="99.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin</title>
        <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
        <time_frame>Baseline to approximately Month 24</time_frame>
        <population>Safety population consisted of all ITT participants from Arms A and C (Phase II) who received at least one dose of study medication. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin</title>
          <description>The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Arms A and C (Phase II) who received at least one dose of study medication. 'Overall Number Analyzed' is the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Prevalence of ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="37"/>
                    <count group_id="O2" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9"/>
                    <measurement group_id="O2" value="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</title>
        <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
        <time_frame>Baseline to approximately Month 24</time_frame>
        <population>Safety population consisted of all ITT participants from Arms E and F (Phase II) who received at least one dose of study medication. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab</title>
          <description>The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have &quot;Treatment-induced ADAs&quot; or &quot;Treatment-enhanced ADA&quot; during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.</description>
          <population>Safety population consisted of all ITT participants from Arms E and F (Phase II) who received at least one dose of study medication. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline Prevalence of ADAs to Polatuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs to Polatuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.3"/>
                    <measurement group_id="O2" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline Prevalence of ADAs to Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="20"/>
                    <count group_id="O2" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-Baseline Incidence of ADAs to Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="19"/>
                    <count group_id="O2" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</title>
        <description>CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</title>
          <description>CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.1" lower_limit="47.18" upper_limit="78.80"/>
                    <measurement group_id="O2" value="63.4" lower_limit="46.94" upper_limit="77.88"/>
                    <measurement group_id="O3" value="42.5" lower_limit="27.04" upper_limit="59.11"/>
                    <measurement group_id="O4" value="15.0" lower_limit="5.71" upper_limit="29.84"/>
                    <measurement group_id="O5" value="65.0" lower_limit="40.78" upper_limit="84.61"/>
                    <measurement group_id="O6" value="33.3" lower_limit="14.59" upper_limit="56.97"/>
                    <measurement group_id="O7" value="36.8" lower_limit="27.63" upper_limit="46.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.8817</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>0.69</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-19.68</ci_lower_limit>
            <ci_upper_limit>20.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0061</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>27.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.66</ci_lower_limit>
            <ci_upper_limit>44.74</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
        <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II Expansion Cohorts and Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Arm G (Phase II Expansion): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
          <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II Expansion Cohorts and Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.0" lower_limit="40.78" upper_limit="84.61"/>
                    <measurement group_id="O2" value="33.3" lower_limit="14.59" upper_limit="56.97"/>
                    <measurement group_id="O3" value="35.7" lower_limit="21.55" upper_limit="51.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="63.54" upper_limit="90.70"/>
                    <measurement group_id="O2" value="80.5" lower_limit="63.13" upper_limit="91.18"/>
                    <measurement group_id="O3" value="47.5" lower_limit="31.51" upper_limit="63.87"/>
                    <measurement group_id="O4" value="17.5" lower_limit="7.34" upper_limit="32.78"/>
                    <measurement group_id="O5" value="85.0" lower_limit="62.11" upper_limit="96.79"/>
                    <measurement group_id="O6" value="33.3" lower_limit="14.59" upper_limit="56.97"/>
                    <measurement group_id="O7" value="42.5" lower_limit="32.91" upper_limit="52.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9523</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>-1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-18.66</ci_lower_limit>
            <ci_upper_limit>16.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0036</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>30.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.48</ci_lower_limit>
            <ci_upper_limit>47.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.9" lower_limit="60.67" upper_limit="88.87"/>
                    <measurement group_id="O2" value="73.2" lower_limit="57.06" upper_limit="85.78"/>
                    <measurement group_id="O3" value="42.5" lower_limit="27.04" upper_limit="59.11"/>
                    <measurement group_id="O4" value="17.5" lower_limit="7.34" upper_limit="32.78"/>
                    <measurement group_id="O5" value="85.0" lower_limit="62.11" upper_limit="96.79"/>
                    <measurement group_id="O6" value="38.1" lower_limit="18.11" upper_limit="61.56"/>
                    <measurement group_id="O7" value="43.4" lower_limit="33.80" upper_limit="53.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6574</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>3.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.14</ci_lower_limit>
            <ci_upper_limit>22.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0128</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>25.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>4.89</ci_lower_limit>
            <ci_upper_limit>42.63</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</title>
        <description>CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</title>
          <description>CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.2" lower_limit="30.09" upper_limit="62.82"/>
                    <measurement group_id="O2" value="19.5" lower_limit="8.82" upper_limit="34.87"/>
                    <measurement group_id="O3" value="20.0" lower_limit="9.05" upper_limit="35.65"/>
                    <measurement group_id="O4" value="5.0" lower_limit="0.61" upper_limit="16.92"/>
                    <measurement group_id="O5" value="20.0" lower_limit="5.73" upper_limit="43.66"/>
                    <measurement group_id="O6" value="14.3" lower_limit="3.05" upper_limit="36.34"/>
                    <measurement group_id="O7" value="14.2" lower_limit="8.14" upper_limit="22.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</title>
        <description>CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</title>
          <description>CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="20"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.0" lower_limit="25.57" upper_limit="57.90"/>
                    <measurement group_id="O2" value="36.6" lower_limit="22.12" upper_limit="53.06"/>
                    <measurement group_id="O3" value="22.5" lower_limit="10.84" upper_limit="38.45"/>
                    <measurement group_id="O4" value="2.5" lower_limit="0.06" upper_limit="13.16"/>
                    <measurement group_id="O5" value="50.0" lower_limit="27.20" upper_limit="72.80"/>
                    <measurement group_id="O6" value="23.8" lower_limit="8.22" upper_limit="47.17"/>
                    <measurement group_id="O7" value="17.9" lower_limit="11.15" upper_limit="26.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="79.5" lower_limit="63.54" upper_limit="90.70"/>
                    <measurement group_id="O2" value="75.6" lower_limit="59.70" upper_limit="87.64"/>
                    <measurement group_id="O3" value="45.0" lower_limit="29.26" upper_limit="61.51"/>
                    <measurement group_id="O4" value="15.0" lower_limit="5.71" upper_limit="29.84"/>
                    <measurement group_id="O5" value="80.0" lower_limit="56.34" upper_limit="94.27"/>
                    <measurement group_id="O6" value="33.3" lower_limit="14.59" upper_limit="56.97"/>
                    <measurement group_id="O7" value="42.5" lower_limit="32.91" upper_limit="52.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.6225</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>3.88</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-14.49</ci_lower_limit>
            <ci_upper_limit>21.72</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0032</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>30.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>9.94</ci_lower_limit>
            <ci_upper_limit>47.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.4" lower_limit="57.87" upper_limit="86.96"/>
                    <measurement group_id="O2" value="80.5" lower_limit="65.13" upper_limit="91.18"/>
                    <measurement group_id="O3" value="40.0" lower_limit="24.86" upper_limit="56.67"/>
                    <measurement group_id="O4" value="15.0" lower_limit="5.71" upper_limit="29.84"/>
                    <measurement group_id="O5" value="80.0" lower_limit="56.34" upper_limit="94.27"/>
                    <measurement group_id="O6" value="38.1" lower_limit="18.11" upper_limit="61.56"/>
                    <measurement group_id="O7" value="41.5" lower_limit="32.02" upper_limit="51.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.4835</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>-6.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.14</ci_lower_limit>
            <ci_upper_limit>12.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0096</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>25.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.39</ci_lower_limit>
            <ci_upper_limit>42.33</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
        <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
          <population>ITT population included all randomized participants in Phase II irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
                <count group_id="O2" value="41"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="40"/>
                <count group_id="O5" value="20"/>
                <count group_id="O6" value="21"/>
                <count group_id="O7" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.7" lower_limit="75.78" upper_limit="97.13"/>
                    <measurement group_id="O2" value="90.2" lower_limit="76.87" upper_limit="97.28"/>
                    <measurement group_id="O3" value="70.0" lower_limit="53.47" upper_limit="83.44"/>
                    <measurement group_id="O4" value="32.5" lower_limit="18.57" upper_limit="49.13"/>
                    <measurement group_id="O5" value="90.0" lower_limit="68.30" upper_limit="98.77"/>
                    <measurement group_id="O6" value="52.4" lower_limit="29.78" upper_limit="74.29"/>
                    <measurement group_id="O7" value="62.3" lower_limit="52.33" upper_limit="71.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9390</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>-0.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-15.07</ci_lower_limit>
            <ci_upper_limit>13.71</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>37.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.64</ci_lower_limit>
            <ci_upper_limit>54.71</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC</title>
        <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
        <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC</title>
          <description>BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN &amp; ELS, score=4 or 5, reduced UT than baseline (BL) &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
          <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="45.80" upper_limit="77.27"/>
                    <measurement group_id="O2" value="25.0" lower_limit="12.69" upper_limit="41.20"/>
                    <measurement group_id="O3" value="42.9" lower_limit="21.82" upper_limit="65.98"/>
                    <measurement group_id="O4" value="57.5" lower_limit="47.57" upper_limit="67.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0005</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Difference in Response Rates</param_type>
            <param_value>37.50</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>15.82</ci_lower_limit>
            <ci_upper_limit>54.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
        <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
          <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="28"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.665" lower_limit="5.782" upper_limit="27.926"/>
                    <measurement group_id="O2" value="4.074" lower_limit="2.563" upper_limit="12.682"/>
                    <measurement group_id="O3" value="16.099" lower_limit="2.825" upper_limit="27.860"/>
                    <measurement group_id="O4" value="11.335" lower_limit="6.242" upper_limit="16.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0245</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.19</ci_lower_limit>
            <ci_upper_limit>0.91</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC</title>
        <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
        <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC</title>
          <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
          <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="10"/>
                <count group_id="O3" value="9"/>
                <count group_id="O4" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.908" lower_limit="5.684" upper_limit="40.674"/>
                    <measurement group_id="O2" value="10.645" lower_limit="3.975" upper_limit="19.647"/>
                    <measurement group_id="O3" value="25.758" lower_limit="9.692" upper_limit="46.752"/>
                    <measurement group_id="O4" value="13.437" lower_limit="8.641" upper_limit="20.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2451</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.60</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.25</ci_lower_limit>
            <ci_upper_limit>1.43</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.491" lower_limit="4.928" upper_limit="16.953"/>
                    <measurement group_id="O2" value="2.037" lower_limit="1.544" upper_limit="3.713"/>
                    <measurement group_id="O3" value="5.125" lower_limit="2.103" upper_limit="18.234"/>
                    <measurement group_id="O4" value="5.881" lower_limit="4.764" upper_limit="7.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.20</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC</title>
        <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)</time_frame>
        <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC</title>
          <description>PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in DLBCL Cohorts irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="40"/>
                <count group_id="O2" value="40"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.248" lower_limit="6.045" upper_limit="13.930"/>
                    <measurement group_id="O2" value="3.713" lower_limit="2.070" upper_limit="4.534"/>
                    <measurement group_id="O3" value="5.848" lower_limit="2.103" upper_limit="11.893"/>
                    <measurement group_id="O4" value="6.965" lower_limit="5.092" upper_limit="9.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.23</ci_lower_limit>
            <ci_upper_limit>0.66</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</title>
        <description>CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator</title>
          <description>CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.8" lower_limit="27.63" upper_limit="46.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately&gt;liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately&gt;liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5" lower_limit="32.91" upper_limit="52.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.4" lower_limit="33.80" upper_limit="53.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
        <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.3" lower_limit="52.33" upper_limit="71.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC</title>
        <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
        <time_frame>Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC</title>
          <description>BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes &amp; ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT markedly higher than liver &amp;/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes &amp; ELS, score=4 or 5, reduced UT than BL &amp; residual mass of any size;residual UT&gt;UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi &amp; no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes &amp; extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.5" lower_limit="47.57" upper_limit="67.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
        <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="66"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.335" lower_limit="6.242" upper_limit="16.197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC</title>
        <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
        <time_frame>From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC</title>
          <description>DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT&gt; background; 2=UT≤mediastinum;3=UT&gt;mediastinum but ≤liver;4=UT moderately&gt;liver;5=UT&gt;than liver &amp;/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL &amp; residual mass of any size at interim for LN &amp; ELS;residual UT&gt;UT in normal bone marrow but&lt;than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN &amp; ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. 'Overall Number Analyzed' are the number of participants with data available for analysis.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.437" lower_limit="8.641" upper_limit="20.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator</title>
        <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator</title>
          <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.881" lower_limit="4.764" upper_limit="7.524"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC</title>
        <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC</title>
          <description>PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.965" lower_limit="5.092" upper_limit="9.823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator</title>
        <description>EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator</title>
          <description>EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.092" lower_limit="4.402" upper_limit="6.867"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II NF Cohorts: Overall Survival (OS)</title>
        <description>OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
        <time_frame>From Month 37 to Month 84 (up to approximately 47 months)</time_frame>
        <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II NF Cohorts: Overall Survival (OS)</title>
          <description>OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.</description>
          <population>ITT population included all randomized participants in Phase II NF Cohort irrespective of whether or not they received the study treatment.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="106"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.320" lower_limit="8.279" upper_limit="16.986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
        <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC</title>
          <description>CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake &gt; mediastinum but ≤ liver; 4=uptake moderately &gt; liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.7" lower_limit="21.55" upper_limit="51.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</title>
        <description>CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator</title>
          <description>CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.5" lower_limit="2.66" upper_limit="22.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</title>
        <description>CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC</title>
          <description>CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.</description>
          <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.3" lower_limit="5.43" upper_limit="28.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
          <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.1" lower_limit="23.57" upper_limit="54.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</title>
        <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
        <time_frame>6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)</time_frame>
        <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment. Values have been rounded off to the nearest whole number.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC</title>
          <description>OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).</description>
          <population>ITT population included all randomized participants in Arm G (Phase II NF Cohort) irrespective of whether or not they received the study treatment. Values have been rounded off to the nearest whole number.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="42"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" lower_limit="19.57" upper_limit="49.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</title>
        <description>PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
        <time_frame>Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
        <population>PK evaluable population included all the ITT participants in Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O5">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O8">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</title>
          <description>PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
          <population>PK evaluable population included all the ITT participants in Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The data is not evaluable as the samples were below lower limit of quantification (BLLQ).</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="654" spread="29.3"/>
                    <measurement group_id="O2" value="617" spread="26.2"/>
                    <measurement group_id="O3" value="719" spread="26.7"/>
                    <measurement group_id="O4" value="718" spread="14.2"/>
                    <measurement group_id="O5" value="492" spread="241.6"/>
                    <measurement group_id="O6" value="643" spread="24.7"/>
                    <measurement group_id="O7" value="453" spread="682.8"/>
                    <measurement group_id="O8" value="472" spread="617.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.4" spread="5887.2"/>
                    <measurement group_id="O2" value="75.9" spread="40.8"/>
                    <measurement group_id="O3" value="90.7" spread="46.1"/>
                    <measurement group_id="O4" value="109" spread="48.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="1626.9"/>
                    <measurement group_id="O2" value="25.4" spread="29.8"/>
                    <measurement group_id="O3" value="28.9" spread="48.6"/>
                    <measurement group_id="O4" value="34.4" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="546.5"/>
                    <measurement group_id="O2" value="12.4" spread="47.9"/>
                    <measurement group_id="O3" value="8.75" spread="77.7"/>
                    <measurement group_id="O4" value="16.6" spread="25.6"/>
                    <measurement group_id="O5" value="4.72" spread="159.8"/>
                    <measurement group_id="O6" value="12.7" spread="120.5"/>
                    <measurement group_id="O7" value="9.05" spread="74.4"/>
                    <measurement group_id="O8" value="13.1" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="685" spread="22.0"/>
                    <measurement group_id="O2" value="683" spread="20.1"/>
                    <measurement group_id="O3" value="803" spread="20.1"/>
                    <measurement group_id="O4" value="834" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.2" spread="26.1"/>
                    <measurement group_id="O2" value="21.1" spread="46.7"/>
                    <measurement group_id="O3" value="15.3" spread="61.9"/>
                    <measurement group_id="O4" value="26.2" spread="22.1"/>
                    <measurement group_id="O5" value="11.2" spread="109.3"/>
                    <measurement group_id="O6" value="20.7" spread="46.4"/>
                    <measurement group_id="O7" value="15.2" spread="30.5"/>
                    <measurement group_id="O8" value="19.6" spread="30.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="748" spread="23.4"/>
                    <measurement group_id="O2" value="754" spread="14.4"/>
                    <measurement group_id="O3" value="734" spread="22.0"/>
                    <measurement group_id="O4" value="716" spread="13.7"/>
                    <measurement group_id="O5" value="689" spread="20.9"/>
                    <measurement group_id="O6" value="645" spread="21.4"/>
                    <measurement group_id="O7" value="829" spread="20.3"/>
                    <measurement group_id="O8" value="709" spread="10.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="3"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="41.1" spread="49.4"/>
                    <measurement group_id="O7" value="53.0" spread="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="1.21" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O6" value="0.180" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="915" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Treatment Completion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="18.7" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O5" value="10.7" spread="181.7"/>
                    <measurement group_id="O6" value="14.2" spread="95.7"/>
                    <measurement group_id="O7" value="14.9" spread="69.4"/>
                    <measurement group_id="O8" value="12.3" spread="109.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</title>
        <description>PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
        <time_frame>Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose</time_frame>
        <population>PK evaluable population included all the ITT participants in Arm G+H (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE</title>
          <description>PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
          <population>PK evaluable population included all the ITT participants in Arm G+H (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="102"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="102"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="653" spread="237"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.6" spread="8.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="667" spread="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.2" spread="8.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="659" spread="156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab</title>
        <description>PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
        <time_frame>Cycle 1 Days 2: pre-dose &amp; 30 min post dose; Cycle 1 Days 8 &amp; 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose &amp; 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 &amp; 24; study treatment completion visit (up to approx. 84 months)</time_frame>
        <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O5">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O8">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab</title>
          <description>PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
          <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>grams per milliliters (g/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.2" spread="28.4"/>
                    <measurement group_id="O2" value="36.6" spread="25.4"/>
                    <measurement group_id="O3" value="37.5" spread="29.1"/>
                    <measurement group_id="O4" value="34.3" spread="20.3"/>
                    <measurement group_id="O5" value="35.4" spread="27.7"/>
                    <measurement group_id="O6" value="34.6" spread="26.2"/>
                    <measurement group_id="O7" value="32.4" spread="22.8"/>
                    <measurement group_id="O8" value="38.3" spread="20.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.43" spread="4393.4"/>
                    <measurement group_id="O2" value="9.01" spread="43.7"/>
                    <measurement group_id="O3" value="10.2" spread="39.3"/>
                    <measurement group_id="O4" value="10.0" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="1784.3"/>
                    <measurement group_id="O2" value="4.26" spread="35.3"/>
                    <measurement group_id="O3" value="4.61" spread="40.6"/>
                    <measurement group_id="O4" value="5.22" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.696" spread="941.2"/>
                    <measurement group_id="O2" value="2.31" spread="54.2"/>
                    <measurement group_id="O3" value="2.20" spread="76.1"/>
                    <measurement group_id="O4" value="3.70" spread="27.4"/>
                    <measurement group_id="O5" value="1.23" spread="203.1"/>
                    <measurement group_id="O6" value="2.48" spread="137.6"/>
                    <measurement group_id="O7" value="2.20" spread="100.6"/>
                    <measurement group_id="O8" value="2.83" spread="41.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.8" spread="25.9"/>
                    <measurement group_id="O2" value="39.5" spread="28.3"/>
                    <measurement group_id="O3" value="43.4" spread="31.1"/>
                    <measurement group_id="O4" value="42.2" spread="22.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="16"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.44" spread="30.5"/>
                    <measurement group_id="O2" value="5.03" spread="59.0"/>
                    <measurement group_id="O3" value="4.61" spread="62.2"/>
                    <measurement group_id="O4" value="6.26" spread="18.3"/>
                    <measurement group_id="O5" value="3.61" spread="97.8"/>
                    <measurement group_id="O6" value="5.72" spread="39.9"/>
                    <measurement group_id="O7" value="4.82" spread="20.8"/>
                    <measurement group_id="O8" value="5.03" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.2" spread="27.2"/>
                    <measurement group_id="O2" value="44.6" spread="11.0"/>
                    <measurement group_id="O3" value="43.0" spread="25.8"/>
                    <measurement group_id="O4" value="47.1" spread="24.2"/>
                    <measurement group_id="O5" value="44.8" spread="24.3"/>
                    <measurement group_id="O6" value="40.6" spread="20.6"/>
                    <measurement group_id="O7" value="55.0" spread="21.3"/>
                    <measurement group_id="O8" value="37.5" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 3, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="23"/>
                    <count group_id="O6" value="18"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.164" spread="51.9"/>
                    <measurement group_id="O2" value="0.771" spread="193.4"/>
                    <measurement group_id="O3" value="0.910" spread="82.8"/>
                    <measurement group_id="O4" value="0.394" spread="27.1"/>
                    <measurement group_id="O5" value="0.265" spread="209.9"/>
                    <measurement group_id="O6" value="0.316" spread="266.2"/>
                    <measurement group_id="O7" value="0.489" spread="174.2"/>
                    <measurement group_id="O8" value="0.543" spread="126.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 6, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="12"/>
                    <count group_id="O7" value="10"/>
                    <count group_id="O8" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0250" spread="0.0"/>
                    <measurement group_id="O2" value="0.0788" spread="230.0"/>
                    <measurement group_id="O3" value="0.219" spread="96.6"/>
                    <measurement group_id="O4" value="0.104" spread="18.5"/>
                    <measurement group_id="O5" value="0.0539" spread="145.7"/>
                    <measurement group_id="O6" value="0.0564" spread="195.7"/>
                    <measurement group_id="O7" value="0.0920" spread="123.5"/>
                    <measurement group_id="O8" value="0.150" spread="206.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 12, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="13"/>
                    <count group_id="O6" value="9"/>
                    <count group_id="O7" value="6"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0250" spread="0.0"/>
                    <measurement group_id="O2" value="0.0250" spread="0.0"/>
                    <measurement group_id="O3" value="0.0298" spread="35.9"/>
                    <measurement group_id="O4" value="0.0250" spread="0.0"/>
                    <measurement group_id="O5" value="0.0250" spread="0.0"/>
                    <measurement group_id="O6" value="0.0301" spread="60.6"/>
                    <measurement group_id="O7" value="0.0250" spread="0.0"/>
                    <measurement group_id="O8" value="0.0250" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 18, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0250" spread="0.0"/>
                    <measurement group_id="O2" value="0.0250" spread="0.0"/>
                    <measurement group_id="O3" value="0.0250" spread="0.0"/>
                    <measurement group_id="O4" value="0.0250" spread="0.0"/>
                    <measurement group_id="O5" value="0.0250" spread="0.0"/>
                    <measurement group_id="O7" value="0.0250" spread="0.0"/>
                    <measurement group_id="O8" value="0.0250" spread="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 24, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0250" spread="0.0"/>
                    <measurement group_id="O2" value="0.0250" spread="0.0"/>
                    <measurement group_id="O3" value="0.0250" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O4" value="0.0250" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated..</measurement>
                    <measurement group_id="O8" value="0.0250" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="4"/>
                    <count group_id="O7" value="3"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0250" spread="0.0"/>
                    <measurement group_id="O2" value="0.0250" spread="0.0"/>
                    <measurement group_id="O4" value="0.0250" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O6" value="1.65" spread="5419.8"/>
                    <measurement group_id="O7" value="1.23" spread="30267.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.279" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O6" value="0.0250" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="42.0" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Treatment Completion Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="27"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="14"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="5.34" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O5" value="3.34" spread="180.5"/>
                    <measurement group_id="O6" value="4.33" spread="69.4"/>
                    <measurement group_id="O7" value="4.57" spread="57.2"/>
                    <measurement group_id="O8" value="3.23" spread="79.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab</title>
        <description>PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
        <time_frame>Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose</time_frame>
        <population>PK evaluable population included all the ITT participants in Arm G+H (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab</title>
          <description>PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
          <population>PK evaluable population included all the ITT participants in Arm G+H (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.9" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.27" spread="4.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="92"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.0" spread="8.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="63"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.41" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2" spread="7.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</title>
        <description>PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
        <time_frame>Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
        <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O5">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O7">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O8">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</title>
          <description>PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
          <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="6"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="36"/>
                <count group_id="O6" value="36"/>
                <count group_id="O7" value="18"/>
                <count group_id="O8" value="18"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="36"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="36"/>
                    <count group_id="O6" value="35"/>
                    <count group_id="O7" value="18"/>
                    <count group_id="O8" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.726" spread="297.5"/>
                    <measurement group_id="O2" value="0.234" spread="80.2"/>
                    <measurement group_id="O3" value="0.397" spread="67.7"/>
                    <measurement group_id="O4" value="0.327" spread="41.4"/>
                    <measurement group_id="O5" value="0.402" spread="80.2"/>
                    <measurement group_id="O6" value="0.315" spread="105.3"/>
                    <measurement group_id="O7" value="0.243" spread="101.8"/>
                    <measurement group_id="O8" value="0.456" spread="103.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.48" spread="100.8"/>
                    <measurement group_id="O2" value="1.84" spread="78.4"/>
                    <measurement group_id="O3" value="1.96" spread="51.5"/>
                    <measurement group_id="O4" value="2.34" spread="21.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.311" spread="93.8"/>
                    <measurement group_id="O2" value="0.531" spread="88.5"/>
                    <measurement group_id="O3" value="0.705" spread="60.0"/>
                    <measurement group_id="O4" value="0.688" spread="19.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="33"/>
                    <count group_id="O7" value="17"/>
                    <count group_id="O8" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0264" spread="70.8"/>
                    <measurement group_id="O2" value="0.158" spread="79.4"/>
                    <measurement group_id="O3" value="0.0512" spread="129.3"/>
                    <measurement group_id="O4" value="0.150" spread="44.4"/>
                    <measurement group_id="O5" value="0.0373" spread="81.5"/>
                    <measurement group_id="O6" value="0.159" spread="80.9"/>
                    <measurement group_id="O7" value="0.0451" spread="76.9"/>
                    <measurement group_id="O8" value="0.186" spread="86.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.185" spread="54.2"/>
                    <measurement group_id="O2" value="0.263" spread="72.7"/>
                    <measurement group_id="O3" value="0.231" spread="53.5"/>
                    <measurement group_id="O4" value="0.345" spread="31.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="32"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0414" spread="102.9"/>
                    <measurement group_id="O2" value="0.133" spread="72.6"/>
                    <measurement group_id="O3" value="0.0511" spread="68.3"/>
                    <measurement group_id="O4" value="0.150" spread="44.3"/>
                    <measurement group_id="O5" value="0.0554" spread="77.3"/>
                    <measurement group_id="O6" value="0.158" spread="58.2"/>
                    <measurement group_id="O7" value="0.0481" spread="83.2"/>
                    <measurement group_id="O8" value="0.141" spread="102.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="23"/>
                    <count group_id="O7" value="15"/>
                    <count group_id="O8" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.234" spread="35.0"/>
                    <measurement group_id="O2" value="0.266" spread="27.0"/>
                    <measurement group_id="O3" value="0.167" spread="39.2"/>
                    <measurement group_id="O4" value="0.257" spread="32.3"/>
                    <measurement group_id="O5" value="0.198" spread="32.0"/>
                    <measurement group_id="O6" value="0.316" spread="38.9"/>
                    <measurement group_id="O7" value="0.195" spread="38.1"/>
                    <measurement group_id="O8" value="0.283" spread="56.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                    <count group_id="O7" value="2"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O7" value="0.738" spread="64.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.0180" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O6" value="0.0180" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                    <count group_id="O7" value="0"/>
                    <count group_id="O8" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="0.114" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Treatment Completion</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="28"/>
                    <count group_id="O6" value="27"/>
                    <count group_id="O7" value="13"/>
                    <count group_id="O8" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0595" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O5" value="0.0506" spread="113.0"/>
                    <measurement group_id="O6" value="0.0749" spread="165.9"/>
                    <measurement group_id="O7" value="0.0682" spread="110.4"/>
                    <measurement group_id="O8" value="0.150" spread="179.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</title>
        <description>PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
        <time_frame>Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose</time_frame>
        <population>PK evaluable population included all the ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE</title>
          <description>PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.</description>
          <population>PK evaluable population included all the ITT participants in Arm G (Phase II NF Cohort) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="103"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="103"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.590" spread="1.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="94"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.229" spread="0.248"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="91"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.316" spread="0.213"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="61"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.186" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.256" spread="0.118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration of Bendamustine</title>
        <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).</description>
        <time_frame>Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose</time_frame>
        <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O5">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O7">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O8">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O9">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O10">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Bendamustine</title>
          <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).</description>
          <population>PK evaluable population included all the ITT participants Phase Ib and Phase II who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="37"/>
                <count group_id="O6" value="39"/>
                <count group_id="O7" value="35"/>
                <count group_id="O8" value="33"/>
                <count group_id="O9" value="18"/>
                <count group_id="O10" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 2: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="37"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="33"/>
                    <count group_id="O9" value="18"/>
                    <count group_id="O10" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O7" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O8" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O9" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O10" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 5 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="35"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="18"/>
                    <count group_id="O10" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="2130" spread="665.6"/>
                    <measurement group_id="O6" value="2810" spread="222.7"/>
                    <measurement group_id="O7" value="2740" spread="550.9"/>
                    <measurement group_id="O8" value="1700" spread="1865.5"/>
                    <measurement group_id="O9" value="3090" spread="68.3"/>
                    <measurement group_id="O10" value="3790" spread="119.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 1h Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="35"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="31"/>
                    <count group_id="O9" value="17"/>
                    <count group_id="O10" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="456" spread="167.8"/>
                    <measurement group_id="O6" value="353" spread="187.9"/>
                    <measurement group_id="O7" value="518" spread="154.2"/>
                    <measurement group_id="O8" value="451" spread="380.2"/>
                    <measurement group_id="O9" value="478" spread="111.4"/>
                    <measurement group_id="O10" value="639" spread="165.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 2h Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="39"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="33"/>
                    <count group_id="O9" value="17"/>
                    <count group_id="O10" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="84.4" spread="173.5"/>
                    <measurement group_id="O6" value="55.1" spread="236.5"/>
                    <measurement group_id="O7" value="93.8" spread="250.5"/>
                    <measurement group_id="O8" value="101" spread="375.8"/>
                    <measurement group_id="O9" value="62.8" spread="104.3"/>
                    <measurement group_id="O10" value="128" spread="196.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 3h Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="33"/>
                    <count group_id="O6" value="38"/>
                    <count group_id="O7" value="34"/>
                    <count group_id="O8" value="32"/>
                    <count group_id="O9" value="17"/>
                    <count group_id="O10" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="20.5" spread="220.1"/>
                    <measurement group_id="O6" value="12.7" spread="246.4"/>
                    <measurement group_id="O7" value="23.5" spread="461.0"/>
                    <measurement group_id="O8" value="21.5" spread="509.9"/>
                    <measurement group_id="O9" value="12.4" spread="132.0"/>
                    <measurement group_id="O10" value="28.2" spread="287.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 2: 4h Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="31"/>
                    <count group_id="O6" value="37"/>
                    <count group_id="O7" value="31"/>
                    <count group_id="O8" value="33"/>
                    <count group_id="O9" value="17"/>
                    <count group_id="O10" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="7.60" spread="278.5"/>
                    <measurement group_id="O6" value="4.58" spread="268.4"/>
                    <measurement group_id="O7" value="8.11" spread="724.8"/>
                    <measurement group_id="O8" value="8.08" spread="615.9"/>
                    <measurement group_id="O9" value="3.30" spread="147.2"/>
                    <measurement group_id="O10" value="6.18" spread="131.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of Rituximab</title>
        <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).</description>
        <time_frame>Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) and Arms A-D (Phase II) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Rituximab</title>
          <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) and Arms A-D (Phase II) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="37"/>
                <count group_id="O4" value="38"/>
                <count group_id="O5" value="34"/>
                <count group_id="O6" value="34"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Days 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="37"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O5" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O6" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Days 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="32"/>
                    <count group_id="O4" value="38"/>
                    <count group_id="O5" value="34"/>
                    <count group_id="O6" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="182" spread="27.2"/>
                    <measurement group_id="O4" value="202" spread="24.5"/>
                    <measurement group_id="O5" value="188" spread="19.9"/>
                    <measurement group_id="O6" value="180" spread="18.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Days 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="36"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="29"/>
                    <count group_id="O6" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="22.8" spread="79.2"/>
                    <measurement group_id="O4" value="20.2" spread="145.9"/>
                    <measurement group_id="O5" value="34.9" spread="89.9"/>
                    <measurement group_id="O6" value="34.6" spread="69.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Days 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="33"/>
                    <count group_id="O5" value="21"/>
                    <count group_id="O6" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="65.1" spread="46.5"/>
                    <measurement group_id="O4" value="62.3" spread="42.7"/>
                    <measurement group_id="O5" value="74.7" spread="50.9"/>
                    <measurement group_id="O6" value="83.3" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="30.6" spread="118.0"/>
                    <measurement group_id="O5" value="298" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O6" value="2.00" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O6" value="165" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Serum Concentration of Obinutuzumab</title>
        <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
        <time_frame>Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)</time_frame>
        <population>PK evaluable population included all the ITT participants who Cohort 1b (Phase 1b) and Arms E and F (Phase II) received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O3">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Serum Concentration of Obinutuzumab</title>
          <description>Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.</description>
          <population>PK evaluable population included all the ITT participants who Cohort 1b (Phase 1b) and Arms E and F (Phase II) received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoint.</population>
          <units>g/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
                <count group_id="O3" value="19"/>
                <count group_id="O4" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cycle 1 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O2" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O3" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                    <measurement group_id="O4" value="NA" spread="NA">The data is not evaluable as the samples were BLLQ.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 1 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="341" spread="22.1"/>
                    <measurement group_id="O4" value="221" spread="105.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 2 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="283" spread="38.4"/>
                    <measurement group_id="O2" value="412" spread="40.8"/>
                    <measurement group_id="O3" value="301" spread="39.3"/>
                    <measurement group_id="O4" value="349" spread="58.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="293" spread="53.8"/>
                    <measurement group_id="O2" value="359" spread="28.9"/>
                    <measurement group_id="O3" value="291" spread="37.9"/>
                    <measurement group_id="O4" value="290" spread="36.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cycle 4 Day 1: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="701" spread="27.4"/>
                    <measurement group_id="O4" value="642" spread="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 3, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.7" spread="47.8"/>
                    <measurement group_id="O2" value="28.8" spread="17.0"/>
                    <measurement group_id="O3" value="38.5" spread="167.8"/>
                    <measurement group_id="O4" value="55.1" spread="119.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 6, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" spread="56.6"/>
                    <measurement group_id="O2" value="5.38" spread="12.4"/>
                    <measurement group_id="O3" value="7.64" spread="412.2"/>
                    <measurement group_id="O4" value="15.8" spread="137.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 12, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.237" spread="717.6"/>
                    <measurement group_id="O2" value="0.389" spread="119.3"/>
                    <measurement group_id="O3" value="0.162" spread="569.7"/>
                    <measurement group_id="O4" value="0.732" spread="18.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 18, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00978" spread="1188.5"/>
                    <measurement group_id="O2" value="0.0107" spread="170.5"/>
                    <measurement group_id="O3" value="0.00842" spread="347.4"/>
                    <measurement group_id="O4" value="0.0460" spread="86.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Follow up on Month 24, Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00203" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O2" value="0.00203" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O4" value="0.00203" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3.09" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O3" value="20.8" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: Pre-dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="0.0626" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unscheduled Visit: 30 min Post Dose</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O4" value="349" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Study Treatment Completion Visit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="367" spread="NA">Since only 1 participant was analyzed, the geometric coefficient of variation was not calculated.</measurement>
                    <measurement group_id="O3" value="242" spread="52.7"/>
                    <measurement group_id="O4" value="232" spread="46.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Cmax was not evaluated for Bendamustine and Rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Cmax was not evaluated for Bendamustine and Rituximab.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="676" spread="176"/>
                    <measurement group_id="O2" value="634" spread="158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="697" spread="129"/>
                    <measurement group_id="O2" value="694" spread="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="763" spread="159"/>
                    <measurement group_id="O2" value="759" spread="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.3" spread="8.57"/>
                    <measurement group_id="O2" value="37.6" spread="9.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6" spread="8.00"/>
                    <measurement group_id="O2" value="40.6" spread="9.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="9.98"/>
                    <measurement group_id="O2" value="44.8" spread="5.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.31" spread="4.00"/>
                    <measurement group_id="O2" value="2.21" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Cmax was not evaluated for Bendamustine and Obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Cmax was not evaluated for Bendamustine and Obinutuzumab.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="738" spread="165"/>
                    <measurement group_id="O2" value="725" spread="104"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="816" spread="168"/>
                    <measurement group_id="O2" value="841" spread="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="749" spread="158"/>
                    <measurement group_id="O2" value="721" spread="97.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.7" spread="9.84"/>
                    <measurement group_id="O2" value="34.9" spread="7.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.0" spread="12.1"/>
                    <measurement group_id="O2" value="43.1" spread="9.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2" spread="11.2"/>
                    <measurement group_id="O2" value="48.2" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.17" spread="1.08"/>
                    <measurement group_id="O2" value="2.39" spread="0.492"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="36"/>
                <count group_id="O2" value="35"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="622" spread="194"/>
                    <measurement group_id="O2" value="661" spread="149"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="703" spread="150"/>
                    <measurement group_id="O2" value="659" spread="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="36"/>
                    <count group_id="O2" value="35"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.7" spread="9.54"/>
                    <measurement group_id="O2" value="35.7" spread="8.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.1" spread="11.4"/>
                    <measurement group_id="O2" value="41.4" spread="8.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.57" spread="2.06"/>
                    <measurement group_id="O2" value="4.23" spread="2.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="188" spread="49.2"/>
                    <measurement group_id="O2" value="191" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Cmax of Bendamustine and Rituximab in Arms B and D</title>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Cmax of Bendamustine and Rituximab in Arms B and D</title>
          <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="38"/>
                <count group_id="O2" value="33"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="34"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.21" spread="2.09"/>
                    <measurement group_id="O2" value="3.85" spread="2.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="38"/>
                    <count group_id="O2" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="207" spread="50.1"/>
                    <measurement group_id="O2" value="183" spread="33.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F</title>
        <description>PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.</description>
        <time_frame>Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F</title>
          <description>PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints.</population>
          <units>ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="692" spread="230"/>
                    <measurement group_id="O2" value="703" spread="211"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>acMMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="845" spread="165"/>
                    <measurement group_id="O2" value="713" spread="70.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.3" spread="8.04"/>
                    <measurement group_id="O2" value="39.0" spread="7.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.1" spread="11.2"/>
                    <measurement group_id="O2" value="37.8" spread="4.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="19"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="1.58"/>
                    <measurement group_id="O2" value="5.47" spread="4.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bendamustine: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Obinutuzumab: Cycle 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="349" spread="72.8"/>
                    <measurement group_id="O2" value="274" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obinutuzumab: Cycle 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="727" spread="217"/>
                    <measurement group_id="O2" value="666" spread="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day*micrograms per milliliter [day*ug/mL]).</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for bendamustine and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day*micrograms per milliliter [day*ug/mL]).</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for bendamustine and rituximab.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2830" spread="12.1"/>
                    <measurement group_id="O2" value="2110" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="298" spread="4.9"/>
                    <measurement group_id="O2" value="214" spread="35.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for bendamustine and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for bendamustine and obinutuzumab.</population>
          <units>day*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2600" spread="34.4"/>
                    <measurement group_id="O2" value="2650" spread="16.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="267" spread="30.2"/>
                    <measurement group_id="O2" value="252" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and rituximab.</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="30"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.29" spread="73.3"/>
                    <measurement group_id="O2" value="3.62" spread="78.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D</title>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D</title>
          <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for rituximab.</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="33"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.86" spread="67.3"/>
                    <measurement group_id="O2" value="3.43" spread="97.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and obinutuzumab.</population>
          <units>h*ug/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.88" spread="28.9"/>
                    <measurement group_id="O2" value="4.10" spread="67.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for bendamustine and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for bendamustine and rituximab.</population>
          <units>mL/day/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" spread="12.9"/>
                    <measurement group_id="O2" value="15.2" spread="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.05" spread="4.7"/>
                    <measurement group_id="O2" value="8.48" spread="35.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for bendamustine and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for bendamustine and obinutuzumab.</population>
          <units>mL/day/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.3" spread="34.9"/>
                    <measurement group_id="O2" value="12.1" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.76" spread="30.6"/>
                    <measurement group_id="O2" value="7.17" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms A and B who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for pola and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms A and B who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for pola and rituximab.</population>
          <units>Liters per hour (L/h)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="30"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="60.8"/>
                    <measurement group_id="O2" value="42.6" spread="66.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: CL of Bendamustine and Rituximab in Arms B and D</title>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: CL of Bendamustine and Rituximab in Arms B and D</title>
          <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema CL was not evaluated for rituximab.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="32"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.4" spread="60.9"/>
                    <measurement group_id="O2" value="46.4" spread="93.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema AUC was not evaluated for pola and obinutuzumab.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Uncojugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.3" spread="33.4"/>
                    <measurement group_id="O2" value="39.9" spread="76.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for bendamustine and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1a (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for bendamustine and rituximab.</population>
          <units>mL/kg</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.0" spread="22.3"/>
                    <measurement group_id="O2" value="82.7" spread="33.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82.3" spread="9.1"/>
                    <measurement group_id="O2" value="76.6" spread="25.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for bendamustine and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Cohort 1b (Phase Ib) who received at least one study treatment and who provided suitable PK samples. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for bendamustine and obinutuzumab.</population>
          <units>mL/kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77.2" spread="38.8"/>
                    <measurement group_id="O2" value="64.7" spread="23.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" spread="38.5"/>
                    <measurement group_id="O2" value="87.9" spread="24.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for pola and rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms A and C who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for pola and rituximab.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.5" spread="86.4"/>
                    <measurement group_id="O2" value="34.3" spread="57.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Vss of Bendamustine and Rituximab in Arms B and D</title>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for rituximab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O2">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Vss of Bendamustine and Rituximab in Arms B and D</title>
          <population>PK evaluable population included all the ITT participants in Arms B and D who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for rituximab.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="31"/>
                    <count group_id="O2" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.9" spread="69.6"/>
                    <measurement group_id="O2" value="33.2" spread="62.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rituximab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)</time_frame>
        <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for pola and obinutuzumab.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>PK evaluable population included all the ITT participants in Arms E and F who received at least one study treatment and who provided suitable PK samples. 'Overall Number Analyzed' are the number of participants with data available for analysis. 'Number Analyzed' is the number of participants with data available for analysis at a specified timepoints. Due to the sparse sample collection schema Vss was not evaluated for pola and obinutuzumab.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Total Ab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Unconjugated MMAE</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>Bendamustine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.2" spread="33.6"/>
                    <measurement group_id="O2" value="31.5" spread="68.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Obinutuzumab</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)</title>
        <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
        <time_frame>Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks</time_frame>
        <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm H (Phase II NF Cohort): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)</title>
          <description>PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.</description>
          <population>As pre-specified in the protocol the analysis of this OM was based on sponsor's discretion however, sponsor opted to not collect data for this OM.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>acMMAE</title>
            </class>
            <class>
              <title>MMAE</title>
            </class>
            <class>
              <title>Total Ab</title>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F</title>
        <description>The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.</description>
        <time_frame>Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)</time_frame>
        <population>ITT population included all randomized participants in Arms A-F (Phase II) irrespective of whether or not they received the study treatment. 'Overall Number Analysed' =number of participants with data available for analysis. 'Number of Participants Analyzed'=number of participants evaluable for this outcome measure. Participants from Arm F did not answer a sufficient number of questions at both baseline and end of treatment visit therefore the average score could not be calculated.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O2">
            <title>Arm B (Phase II Randomization): BR in FL</title>
            <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O3">
            <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
          </group>
          <group group_id="O4">
            <title>Arm D (Phase II Randomization): BR in DLBCL</title>
            <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
          </group>
          <group group_id="O5">
            <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
            <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
          <group group_id="O6">
            <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
            <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
          </group>
        </group_list>
        <measure>
          <title>Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F</title>
          <description>The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.</description>
          <population>ITT population included all randomized participants in Arms A-F (Phase II) irrespective of whether or not they received the study treatment. 'Overall Number Analysed' =number of participants with data available for analysis. 'Number of Participants Analyzed'=number of participants evaluable for this outcome measure. Participants from Arm F did not answer a sufficient number of questions at both baseline and end of treatment visit therefore the average score could not be calculated.</population>
          <units>Points on scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="11"/>
                <count group_id="O4" value="12"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.5" spread="1.1"/>
                    <measurement group_id="O3" value="0.4" spread="0.6"/>
                    <measurement group_id="O4" value="0.6" spread="0.7"/>
                    <measurement group_id="O5" value="0.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O5" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="0.5" spread="1.3"/>
                    <measurement group_id="O3" value="0.3" spread="0.4"/>
                    <measurement group_id="O4" value="1.0" spread="1.1"/>
                    <measurement group_id="O5" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="10"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.5"/>
                    <measurement group_id="O2" value="0.7" spread="1.5"/>
                    <measurement group_id="O3" value="0.1" spread="0.1"/>
                    <measurement group_id="O4" value="0.9" spread="0.1"/>
                    <measurement group_id="O5" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="9"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.3"/>
                    <measurement group_id="O4" value="0.7" spread="0.8"/>
                    <measurement group_id="O5" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 5</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.6" spread="1.4"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                    <measurement group_id="O4" value="0.6" spread="0.6"/>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.5"/>
                    <measurement group_id="O4" value="0.7" spread="1.0"/>
                    <measurement group_id="O5" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 7</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="8"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="0.9" spread="1.9"/>
                    <measurement group_id="O3" value="0.2" spread="0.3"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="7"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                    <measurement group_id="O3" value="0.2" spread="0.5"/>
                    <measurement group_id="O4" value="0.6" spread="0.9"/>
                    <measurement group_id="O5" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 9</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.9"/>
                    <measurement group_id="O2" value="0.5" spread="0.9"/>
                    <measurement group_id="O3" value="0.2" spread="0.3"/>
                    <measurement group_id="O4" value="0.5" spread="0.7"/>
                    <measurement group_id="O5" value="0.1" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 10</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.9"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.1" spread="0.1"/>
                    <measurement group_id="O4" value="0.2" spread="0.4"/>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 11</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="13"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="6"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.0"/>
                    <measurement group_id="O2" value="0.5" spread="0.9"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="1.4"/>
                    <measurement group_id="O2" value="0.9" spread="2.0"/>
                    <measurement group_id="O3" value="0.3" spread="0.4"/>
                    <measurement group_id="O4" value="0.3" spread="0.6"/>
                    <measurement group_id="O5" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 13</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.2"/>
                    <measurement group_id="O2" value="0.6" spread="1.6"/>
                    <measurement group_id="O3" value="0.3" spread="0.4"/>
                    <measurement group_id="O4" value="0.2" spread="0.4"/>
                    <measurement group_id="O5" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 14</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.2"/>
                    <measurement group_id="O2" value="0.7" spread="1.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.3"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.2" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="1.7"/>
                    <measurement group_id="O3" value="0.4" spread="0.5"/>
                    <measurement group_id="O4" value="0.4" spread="0.4"/>
                    <measurement group_id="O5" value="0.9" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.5"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                    <measurement group_id="O3" value="0.4" spread="0.4"/>
                    <measurement group_id="O4" value="0.4" spread="0.5"/>
                    <measurement group_id="O5" value="0.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 17</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="1.8"/>
                    <measurement group_id="O3" value="0.5" spread="0.7"/>
                    <measurement group_id="O4" value="0.4" spread="0.6"/>
                    <measurement group_id="O5" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 18</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.7" spread="1.8"/>
                    <measurement group_id="O3" value="0.3" spread="0.4"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                    <measurement group_id="O5" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 19</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="2.0"/>
                    <measurement group_id="O3" value="0.4" spread="0.7"/>
                    <measurement group_id="O4" value="0.5" spread="0.8"/>
                    <measurement group_id="O5" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 20</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="1.9"/>
                    <measurement group_id="O3" value="0.6" spread="0.8"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                    <measurement group_id="O5" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="3"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.9" spread="1.9"/>
                    <measurement group_id="O3" value="0.5" spread="0.5"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                    <measurement group_id="O5" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 22</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="2.0"/>
                    <measurement group_id="O3" value="0.9" spread="1.5"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 23</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O2" value="0.8" spread="2.2"/>
                    <measurement group_id="O3" value="0.6" spread="0.7"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="4"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.6"/>
                    <measurement group_id="O2" value="1.0" spread="2.3"/>
                    <measurement group_id="O3" value="0.5" spread="0.7"/>
                    <measurement group_id="O4" value="0.0" spread="0.1"/>
                    <measurement group_id="O5" value="0.3" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 25</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.2" spread="0.2"/>
                    <measurement group_id="O3" value="0.3" spread="0.4"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 26</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.8"/>
                    <measurement group_id="O2" value="3.3" spread="4.4"/>
                    <measurement group_id="O3" value="0.4" spread="0.6"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 27</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="1.1" spread="2.5"/>
                    <measurement group_id="O3" value="0.5" spread="0.6"/>
                    <measurement group_id="O4" value="0.1" spread="0.1"/>
                    <measurement group_id="O5" value="0.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 28</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.6"/>
                    <measurement group_id="O2" value="1.2" spread="2.6"/>
                    <measurement group_id="O3" value="0.5" spread="0.7"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 29</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="0.8" spread="2.1"/>
                    <measurement group_id="O3" value="0.7" spread="0.7"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 30</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.1"/>
                    <measurement group_id="O2" value="0.7" spread="1.9"/>
                    <measurement group_id="O3" value="0.8" spread="0.8"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 31</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.1"/>
                    <measurement group_id="O3" value="1.3" spread="0.9"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.1" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                    <measurement group_id="O3" value="1.0" spread="0.9"/>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 33</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="3"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="1.0" spread="1.0"/>
                    <measurement group_id="O5" value="0.2" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 34</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.2"/>
                    <measurement group_id="O2" value="1.3" spread="2.4"/>
                    <measurement group_id="O3" value="0.8" spread="0.5"/>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 35</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="1.2" spread="0.7"/>
                    <measurement group_id="O4" value="0.6" spread="0.9"/>
                    <measurement group_id="O5" value="0.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.3"/>
                    <measurement group_id="O2" value="0.2" spread="0.3"/>
                    <measurement group_id="O3" value="1.2" spread="0.6"/>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 37</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.1" spread="0.1"/>
                    <measurement group_id="O3" value="1.1" spread="0.8"/>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 38</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.4"/>
                    <measurement group_id="O2" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="1.5" spread="0.4"/>
                    <measurement group_id="O5" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 39</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.9"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="1.5" spread="0.5"/>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.9" spread="0.4"/>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 41</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.6"/>
                    <measurement group_id="O2" value="0.7" spread="1.6"/>
                    <measurement group_id="O3" value="1.4" spread="1.2"/>
                    <measurement group_id="O5" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 42</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.5"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 43</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.4"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O4" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 44</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="0.3"/>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 45</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="0.2"/>
                    <measurement group_id="O3" value="1.0" spread="1.2"/>
                    <measurement group_id="O5" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 46</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="0.7"/>
                    <measurement group_id="O2" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 47</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                    <measurement group_id="O3" value="0.2" spread="0.2"/>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 49</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.1" spread="1.4"/>
                    <measurement group_id="O5" value="0.3" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 50</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="0.2"/>
                    <measurement group_id="O2" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 51</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.2"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 52</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="0.4" spread="0.5"/>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 53</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="0.7" spread="1.5"/>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 54</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.6"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 55</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="0.5"/>
                    <measurement group_id="O2" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.3"/>
                    <measurement group_id="O2" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.0" spread="0.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 57</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.5" spread="2.1"/>
                    <measurement group_id="O5" value="0.2" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 58</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.6"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 59</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.1"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 61</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="2"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.3"/>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                    <measurement group_id="O3" value="1.5" spread="2.1"/>
                    <measurement group_id="O5" value="0.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 62</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 63</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 64</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="1.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.1" spread="0.2"/>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 65</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.0"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="0.8" spread="1.3"/>
                    <measurement group_id="O5" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 66</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 67</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.3"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.9" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 68</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="1.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 69</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O2" value="0.3" spread="0.5"/>
                    <measurement group_id="O3" value="1.5" spread="2.1"/>
                    <measurement group_id="O5" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 70</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.0"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="1.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 71</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.1"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.9" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 73</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.3"/>
                    <measurement group_id="O2" value="0.0" spread="0.0"/>
                    <measurement group_id="O3" value="1.3" spread="1.8"/>
                    <measurement group_id="O5" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 74</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="0.7"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 75</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="0.0"/>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="1.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 76</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 77</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.9" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 78</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="1.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 79</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="1.4" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 80</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="1.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 81</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 82</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 83</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="0"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 85</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 86</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O3" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.6" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 89</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 90</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 91</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 92</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 93</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 94</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 95</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.5" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 97</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 98</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.0" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 99</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 100</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 101</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 102</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 103</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.3" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 104</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.2" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 105</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="0.1" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                    <measurement group_id="O5" value="0.8" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 107</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 108</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                    <count group_id="O5" value="1"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="0.7" spread="NA">SD is not evaluable when only one participant is analyzed</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Treatment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="12"/>
                    <count group_id="O5" value="5"/>
                    <count group_id="O6" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.6"/>
                    <measurement group_id="O2" value="0.6" spread="1.8"/>
                    <measurement group_id="O3" value="0.5" spread="0.8"/>
                    <measurement group_id="O4" value="0.8" spread="1.0"/>
                    <measurement group_id="O5" value="0.1" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From Baseline up to study completion/discontinuation (up to approximately 84 months)</time_frame>
      <desc>All-Cause Mortality were reported for the ITT population. ITT population=participants who were randomized, whether or not the participants received the assigned treatment. Serious and non-serious adverse events were reported for safety population. Safety population=participants who received at least one dose of study medication.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="E2">
          <title>Cohort 1a (Phase Ib Safety Run-In): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine, 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="E3">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="E4">
          <title>Cohort 1b (Phase Ib Safety Run-In): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="E5">
          <title>Arm A (Phase II Randomization): Pola+BR in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="E6">
          <title>Arm B (Phase II Randomization): BR in FL</title>
          <description>Participants with FL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 28 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="E7">
          <title>Arm C (Phase II Randomization): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
        <group group_id="E8">
          <title>Arm D (Phase II Randomization): BR in DLBCL</title>
          <description>Participants with DLBCL received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1 (each cycle is 21 days), thereafter on Days 1 and 2 of Cycles 2 to 6 in combination with rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6.</description>
        </group>
        <group group_id="E9">
          <title>Arm E (Phase II Expansion): Pola+BG in FL</title>
          <description>Participants with FL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 28 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="E10">
          <title>Arm F (Phase II Expansion): Pola+BG in DLBCL</title>
          <description>Participants with DLBCL received pola, 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and obinutuzumab 1000 mg, as IV infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 in combination with pola.</description>
        </group>
        <group group_id="E11">
          <title>Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL</title>
          <description>Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA version 24.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="26" subjects_at_risk="40"/>
                <counts group_id="E8" subjects_affected="30" subjects_at_risk="40"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="18" subjects_at_risk="21"/>
                <counts group_id="E11" subjects_affected="65" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="57" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SUPRAVENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ATRIAL THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DUODENAL ULCER HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OBSTRUCTION GASTRIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MULTIPLE ORGAN DYSFUNCTION SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>HEPATIC CIRRHOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERTRANSAMINASAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ISCHAEMIC HEPATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CEREBRAL TOXOPLASMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS CHORIORETINITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS ENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL BACTERIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GIARDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HEPATITIS E</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HUMAN ANAPLASMOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INFECTED LYMPHOCELE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MENINGOENCEPHALITIS HERPETIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PLEURAL INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMOCYSTIS JIROVECII PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA CYTOMEGALOVIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA FUNGAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA PNEUMOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESPIRATORY SYNCYTIAL VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION VIRAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RHINOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>COVID-19 PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DISSEMINATED VARICELLA ZOSTER VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS SITE CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HEAD INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL FEVER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MORAXELLA TEST POSITIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TUMOUR LYSIS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FLANK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA GASTRIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ADENOCARCINOMA OF COLON</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INTESTINAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTIC LEUKAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SQUAMOUS CELL CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EPIGLOTTIC CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PANCREATIC CARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE INTRACRANIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYDROCEPHALUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LEUKOENCEPHALOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BRAIN OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERVENTILATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LUNG DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG ERUPTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH ERYTHEMATOUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DISTRIBUTIVE SHOCK</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA version 24.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="38"/>
                <counts group_id="E6" subjects_affected="39" subjects_at_risk="41"/>
                <counts group_id="E7" subjects_affected="36" subjects_at_risk="39"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="39"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="19" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="103" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="24" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="13" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E8" events="28" subjects_affected="19" subjects_at_risk="39"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="6" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" events="35" subjects_affected="27" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="19" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="17" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="31" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E6" events="18" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E7" events="27" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E8" events="63" subjects_affected="21" subjects_at_risk="39"/>
                <counts group_id="E9" events="10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" events="30" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E11" events="73" subjects_affected="35" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="13" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E7" events="18" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E8" events="50" subjects_affected="19" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E10" events="10" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E11" events="40" subjects_affected="19" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>COAGULOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMOLYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMOLYTIC ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LYMPHADENOPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>IMMUNE THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BUNDLE BRANCH BLOCK RIGHT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SINUS TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK FIRST DEGREE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOACUSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EAR PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>EYE DISCHARGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EYE PRURITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OCULAR HYPERAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VISION BLURRED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="14" subjects_affected="12" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN LOWER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>APHTHOUS ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="10" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E7" events="9" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E8" events="8" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" events="11" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E10" events="10" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E11" events="27" subjects_affected="20" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="8" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" events="27" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E6" events="11" subjects_affected="9" subjects_at_risk="41"/>
                <counts group_id="E7" events="13" subjects_affected="11" subjects_at_risk="39"/>
                <counts group_id="E8" events="28" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E9" events="22" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E10" events="18" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E11" events="48" subjects_affected="36" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FLATULENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="35" subjects_affected="22" subjects_at_risk="38"/>
                <counts group_id="E6" events="25" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E7" events="19" subjects_affected="16" subjects_at_risk="39"/>
                <counts group_id="E8" events="14" subjects_affected="12" subjects_at_risk="39"/>
                <counts group_id="E9" events="21" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E10" events="16" subjects_affected="11" subjects_at_risk="20"/>
                <counts group_id="E11" events="38" subjects_affected="34" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ODYNOPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="12" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" events="11" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E7" events="8" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" events="11" subjects_affected="7" subjects_at_risk="39"/>
                <counts group_id="E9" events="10" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E10" events="10" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E11" events="18" subjects_affected="17" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ANAL SPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEFAECATION URGENCY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DIVERTICULUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GINGIVAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GINGIVAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LIP DRY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MOUTH ULCERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NONINFECTIVE GINGIVITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RECTAL DISCHARGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="9" subjects_affected="7" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="8" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E8" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="13" subjects_affected="12" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="20" subjects_affected="16" subjects_at_risk="38"/>
                <counts group_id="E6" events="22" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E7" events="17" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E8" events="20" subjects_affected="14" subjects_at_risk="39"/>
                <counts group_id="E9" events="22" subjects_affected="13" subjects_at_risk="20"/>
                <counts group_id="E10" events="15" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E11" events="25" subjects_affected="22" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="11" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="15" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E8" events="14" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E11" events="27" subjects_affected="22" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PRURITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CHEST DISCOMFORT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EARLY SATIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GAIT DISTURBANCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SWELLING</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGAMMAGLOBULINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HERPES VIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORAL HERPES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="10" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="8" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CANDIDA INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIUM DIFFICILE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYSTITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CYTOMEGALOVIRUS VIRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EAR INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FOLLICULITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH PUSTULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INFUSION RELATED REACTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ARTHROPOD BITE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>COMMINUTED FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ASPARTATE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD ALKALINE PHOSPHATASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD BILIRUBIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GAMMA-GLUTAMYLTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="8" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LIPASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="7" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LYMPHOCYTE COUNT DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="10" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="16" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="15" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="37" subjects_affected="14" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="18" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="14" subjects_affected="14" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>WEIGHT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="16" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="6" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="7" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="29" subjects_affected="9" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>AMYLASE INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD CALCIUM DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD MAGNESIUM DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BLOOD PHOSPHORUS DECREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EASTERN COOPERATIVE ONCOLOGY GROUP PERFORMANCE STATUS WORSENED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LIVER FUNCTION TEST ABNORMAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TRANSAMINASES INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TROPONIN I INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TROPONIN INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DECREASED APPETITE</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="13" subjects_affected="10" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E8" events="11" subjects_affected="10" subjects_at_risk="39"/>
                <counts group_id="E9" events="7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" events="10" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E11" events="30" subjects_affected="27" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="9" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERURICAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="7" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="9" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" events="6" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="7" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E9" events="9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" events="20" subjects_affected="15" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="18" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="6" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="6" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERPHOSPHATAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VITAMIN D DEFICIENCY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="6" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="8" subjects_affected="7" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BONE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCULAR WEAKNESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CERVICAL SPINAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>GROIN PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCLE TIGHTNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL CHEST PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MUSCULOSKELETAL STIFFNESS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>HODGKIN'S DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MYELODYSPLASTIC SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TUMOUR PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ENDOMETRIAL ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="11" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="5" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="38"/>
                <counts group_id="E6" events="6" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="6" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="14" subjects_affected="12" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEUROPATHY PERIPHERAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="9" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="10" subjects_affected="9" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="16" subjects_affected="15" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" events="8" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PERIPHERAL MOTOR NEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PERIPHERAL SENSORY NEUROPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="7" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>POST HERPETIC NEURALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>AMNESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSKINESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NEURALGIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PERONEAL NERVE PALSY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>POLYNEUROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RESTLESS LEGS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SCIATICA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SINUS HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TASTE DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ANXIETY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="10" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DELIRIUM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>IRRITABILITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>POLLAKIURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>URINARY INCONTINENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ACUTE KIDNEY INJURY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="4" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ANURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>ERECTILE DYSFUNCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TESTICULAR PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TESTICULAR SWELLING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VAGINAL DISCHARGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="7" subjects_affected="6" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="10" subjects_affected="8" subjects_at_risk="39"/>
                <counts group_id="E8" events="6" subjects_affected="6" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="16" subjects_affected="13" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPHONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="4" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E9" events="7" subjects_affected="7" subjects_at_risk="20"/>
                <counts group_id="E10" events="7" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E11" events="4" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DYSPNOEA EXERTIONAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NASAL CONGESTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>OROPHARYNGEAL PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="6" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PRODUCTIVE COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RHINORRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>THROAT IRRITATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>UPPER-AIRWAY COUGH SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HAEMOPTYSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NASAL DISCHARGE DISCOLOURATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORGANISING PNEUMONIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PNEUMONITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RHINITIS ALLERGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SINUS CONGESTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SINUS PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>TACHYPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="10" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERHIDROSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>NIGHT SWEATS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="3" subjects_affected="3" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="4" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="4" subjects_at_risk="39"/>
                <counts group_id="E8" events="6" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="9" subjects_affected="8" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" events="5" subjects_affected="3" subjects_at_risk="38"/>
                <counts group_id="E6" events="5" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="5" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" events="3" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="8" subjects_affected="5" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH MACULO-PAPULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>URTICARIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="2" subjects_affected="2" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>DERMATITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>RASH MACULAR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>SKIN DISCOLOURATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>FLUSHING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="3" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="3" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="2" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="2" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" events="1" subjects_affected="1" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="38"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="5" subjects_affected="5" subjects_at_risk="39"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="4" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" events="12" subjects_affected="10" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>ORTHOSTATIC HYPOTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="38"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PALLOR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
              <event>
                <sub_title>PHLEBITIS SUPERFICIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="38"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="39"/>
                <counts group_id="E8" events="0" subjects_affected="0" subjects_at_risk="39"/>
                <counts group_id="E9" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" events="0" subjects_affected="0" subjects_at_risk="106"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Communications</name_or_title>
      <organization>Hoffmann-La Roche</organization>
      <phone>800 821-8590</phone>
      <email>genentech@druginfo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02257567
org study id: GO29365
secondary id: 2014-001361-28
nct id: NCT02257567
lead sponsor: 
is fda regulated drug: Yes
is fda regulated device: No
This study is a multicenter, open-label study of polatuzumab vedotin administered by
      intravenous (IV) infusion in combination with standard doses of bendamustine (B) and
      rituximab (R) or obinutuzumab (G) in participants with relapsed or refractory follicular
      lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL). The study comprises two stages: a
      Phase Ib safety run-in stage and a Phase II stage. The anticipated time on treatment is 18
      weeks for participants with DLBCL and 24 weeks for participants with FL.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Phase Ib: Percentage of Participants With Adverse Events (AEs)
time frame: From the study start up to the end of the study (up to approximately 84 months)
description: An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events. AEs were reported based on the National Cancer Institute Common Terminology Criteria for AEs, version 4.0 (NCI-CTCAE, v4.0).
measure: Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs
time frame: From Month 37 to Month 84 (up to approximately 47 months)
description: An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
measure: Cohort 1a (Phase Ib): Percentage of Participants With Treatment Emergent Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin
time frame: Baseline up to approximately Month 24
description: The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 titer unit (t.u.) greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
measure: Cohort 1b (Phase Ib): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
time frame: Baseline up to approximately Month 24
description: The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
measure: Arms G+H: (Phase II NF Cohorts): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin (Lyophilized)
time frame: From Month 37 to Month 84 (up to approximately 47 months)
description: The number of participants with positive results for ADA against lyophilized pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
measure: Phase II Randomized and NF Cohorts: Percentage of Participants With Complete Response (CR) at Primary Response Assessment (PRA) Based on Positron Emission Tomography (PET)-Computed Tomography (CT) Scan as Determined by Independent Review Committee (IRC)
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: CR was assessed by IRC at PRA according to Modified Lugano Response Criteria (MLRC). Per MLRC, CR based on PET-CT was defined as complete metabolic response (MR) in lymph nodes and extralymphatic sites (ELS) with a score of 1, 2, or 3 with or without residual mass, on 5-point scale (5PS) where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of fluorodeoxyglucose (FDG)-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, immunohistochemistry (IHC) negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
measure: Arm H (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
time frame: 6-8 weeks after Cycle 6, Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
measure: Arm G (Phase II NF Cohort): Area Under Concentration-Time Curve (AUC) of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks
description: Pharmacokinetic (PK) of three pola-related analytes: antibody conjugated monomethyl auristatin E (acMMAE), total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is nanograms*day per milliliters.
measure: Arm G (Phase II NF Cohort): Maximum Concentration (Cmax) of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Arm G (Phase II NF Cohort): Systemic Clearance (CL) of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. Unit of measure for CL is milliliters per day per kilograms (mL/day/kg)
measure: Arm G (Phase II NF Cohort): Steady-State Volume of Distribution (Vss) of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: Percentage of Participants With AEs
time frame: From the study start up to the end of the study (up to approximately 84 months)
description: An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
measure: Arms A and C (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin
time frame: Baseline to approximately Month 24
description: The number of participants with positive results for ADA against pola at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
measure: Arms E and F (Phase II): Percentage of Participants With Treatment Emergent ADAs to Polatuzumab Vedotin and Obinutuzumab
time frame: Baseline to approximately Month 24
description: The number of participants with positive results for ADA against pola and obinutuzumab at Baseline and at any of the post-baseline assessment time-points were reported. Participants positive at any post-baseline time points were post-baseline evaluable participants determined to have "Treatment-induced ADAs" or "Treatment-enhanced ADA" during the study period. Treatment-induced ADA = negative or missing baseline ADA result(s) and at least one positive post-baseline ADA result. Treatment-enhanced ADA = a participant with positive ADA result at baseline who has one or more post-baseline titer results that are at least 0.60 t.u. greater than the baseline titer result. Treatment emergent ADA is the sum of treatment-induced ADAs and treatment enhanced ADAs. Values have been rounded off to the nearest whole number.
measure: Phase II: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: CR was assessed by investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
measure: Phase II Expansion Cohorts and Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
measure: Phase II: Percentage of Participants With Objective Response (OR) at PRA Based on PET-CT as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
measure: Phase II: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions; no new lesions and no evidence of FDG-avid disease in bone marrow. Bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
measure: Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: CR was determined by investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 centimetres (cm) in in longest transverse diameter (LDi) and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
measure: Phase II: Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: CR was determined by IRC a at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts). As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.
measure: Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in sum of the products of greatest diameters (SPD) of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
measure: Phase II: Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts) or last dose of study drug (up to approximately 28 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; bone marrow normal by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts and 28 days for FL cohorts).
measure: Phase II: Percentage of Participants With Best Objective Response (BOR) Based on PET-CT or CT Only as Determined by the Investigator
time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
description: BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN & ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT markedly higher than liver &/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN & ELS, score=4 or 5, reduced UT than baseline (BL) & residual mass of any size;residual UT>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi & no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes & extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
measure: DLBCL Cohorts: Percentage of Participants With BOR Based PET-CT or CT Only as Determined by IRC
time frame: Up to every 6 months until disease progression, withdrawal or study completion (up to approximately 84 months)
description: BOR=CR/PR per PET-CT/CT per MLRC.CR per PET-CT=complete MR in LN & ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no uptake(UT) above background;2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT markedly higher than liver &/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in LN & ELS, score=4 or 5, reduced UT than baseline (BL) & residual mass of any size;residual UT>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi & no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes & extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
measure: DLBCL Cohorts: Duration of Response (DOR) Based on PET-CT or CT Only as Determined by the Investigator
time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
description: DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT> background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT>than liver &/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL & residual mass of any size at interim for LN & ELS;residual UT>UT in normal bone marrow but<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN & ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
measure: DLBCL Cohorts: DOR Based on PET-CT or CT Only as Determined by the IRC
time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (up to approximately 84 months)
description: DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT> background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT>than liver &/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL & residual mass of any size at interim for LN & ELS;residual UT>UT in normal bone marrow but<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN & ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
measure: DLBCL Cohorts: Progression Free Survival (PFS) Based on PET-CT or CT Only as Determined by the Investigator
time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
description: PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: DLBCL Cohorts: PFS Based on PET-CT or CT Only as Determined by the IRC
time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (up to approximately 84 months)
description: PFS was defined as the time randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: Phase II NF Cohort: Percentage of Participants With CR at PRA Based on PET-CT as Determined by the Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: CR was assessed by Investigator at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
measure: Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately>liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
measure: Phase II NF Cohort: Percentage of Participants With OR at PRA Based on PET-CT as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC according to MLRC. Per MLRC, CR based on PET-CT= complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass on 5PS, where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions ; no new lesions and no evidence of FDG-avid disease in bone marrow, bone marrow normal by morphology; if indeterminate, IHC negative. PR based on PET-CT was defined as partial MR in lymph nodes and ELS with a score of 4 or 5 with reduced uptake compared with baseline and residual mass(es) of any size at interim, residual uptake higher than uptake in normal bone marrow but reduced compared with baseline (diffuse uptake compatible with reactive changes from chemotherapy allowed).
measure: Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the Investigator
time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
description: BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes & ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT markedly higher than liver &/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes & ELS, score=4 or 5, reduced UT than BL & residual mass of any size;residual UT>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi & no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes & extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
measure: Phase II NF Cohorts: Percentage of Participants With BOR Based on PET-CT or CT Only as Determined by the IRC
time frame: Up to every 6 months until disease progression, withdrawal or study completion (from Month 37 to Month 84 [up to approximately 47 months])
description: BOR=CR/PR per PET-CT/CT per MLRC. CR per PET-CT=complete MR in lymph nodes & ELS, score=1, 2,3 with/without a residual mass on 5-PS; 1=no UT above background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT markedly higher than liver &/or new lesions;no evidence of FDG-avid disease, bone marrow morphology=normal;if indeterminate, is IHC negative.PR per PET-CT=partial MR in lymph nodes & ELS, score=4 or 5, reduced UT than BL & residual mass of any size;residual UT>UT in normal marrow but reduced than BL.CR per CT=complete radiologic response with target nodes/nodal masses regressed to ≤1.5cm in LDi & no ELS of disease, absences of non-measured lesion;organ enlargement regressed to normal;no new lesions;bone marrow= normal;if indeterminate, is IHC negative.PR per CT=≥50% decrease in SPD of up to 6 target nodes & extranodal sites;non-measured lesions=absent/normal/regressed/no increase;spleen=regressed by ≥50% in length beyond normal, no new lesions.
measure: Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the Investigator
time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
description: DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per investigator per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT> background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT>than liver &/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL & residual mass of any size at interim for LN & ELS;residual UT>UT in normal bone marrow but<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN & ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
measure: Phase II NF Cohort: DOR Based on PET-CT or CT Only as Determined by the IRC
time frame: From the date of the first occurrence of a documented CR or PR to the date of disease progression, relapse, or death from any cause whichever occur first (from Month 37 to Month 84 [up to approximately 47 months])
description: DOR=first occurrence of CR/PR to disease progression/relapse/death per PET-CT/CT, per IRC per MLRC.CR per PET-CT=score 1/2/3 with/without a residual mass on 5-PS for LN and ELS;1=no UT> background; 2=UT≤mediastinum;3=UT>mediastinum but ≤liver;4=UT moderately>liver;5=UT>than liver &/or new lesions;bone marrow morphology=no evidence of FDG-avid disease, normal;if indeterminate IHC negative.PR per PET-CT=score of 4/5 with reduced UT compared to BL & residual mass of any size at interim for LN & ELS;residual UT>UT in normal bone marrow but<than BL. CR per CT=target nodes/nodal masses regressed to ≤1.5cm in LDi no ELS of disease for LN & ELS, no non-measured lesion, organ enlargement regressed to normal; bone marrow=normal morphology; if indeterminate, IHC negative. PR per CT= ≥50% decrease SPD of 6 target measurable LN and extranodal sites, absent/normal/regressed but no increase in non-measured lesions, spleen ≥50% in length beyond normal involvement, no new sites of lesions.
measure: Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the Investigator
time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
description: PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the investigators assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: Phase II NF Cohort: PFS Based on PET-CT or CT Only as Determined by the IRC
time frame: From the date of randomization or first treatment to the first occurrence of progression or relapse, or death from any cause (from Month 37 to Month 84 [up to approximately 47 months])
description: PFS was defined as the time from randomization or from first study treatment (for obinuzumab arms) to the first occurrence of disease progression, relapse or death, from any cause based on PET-CT or CT only, as determined by the IRC assessment. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: Phase II NF Cohort: Event-Free Survival (EFS) Based on PET-CT or CT Only, as Determined by the Investigator
time frame: From Month 37 to Month 84 (up to approximately 47 months)
description: EFS was defined as time from randomization to disease progression or relapse, as assessed by the investigator or death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: Phase II NF Cohorts: Overall Survival (OS)
time frame: From Month 37 to Month 84 (up to approximately 47 months)
description: OS was defined as the time from the date of randomization or first treatment (for obinutuzumab arms) to the date of death from any cause. As pre-specified in the protocol data reported is combined for Arms G and H.
measure: Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on PET-CT as Determined by the IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: CR was assessed by IRC at PRA according to MLRC. Per MLRC, CR based on PET-CT was defined as complete MR in lymph nodes and ELS with a score of 1, 2, or 3 with or without residual mass, on 5PS where 1=no uptake above background; 2=uptake ≤ mediastinum; 3=uptake > mediastinum but ≤ liver; 4=uptake moderately > liver; 5=uptake markedly higher than liver and/or new lesions no evidence of FDG-avid disease in bone marrow. Bone marrow is normal by morphology; if indeterminate, IHC negative. As pre-specified in the protocol data reported is combined for Arms G and H. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts) or after final dose of study treatment. Values have been rounded off to the nearest whole number.
measure: Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: CR was determined by Investigator at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
measure: Arm G (Phase II NF Cohort): Percentage of Participants With CR at PRA Based on CT Only as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to approximately 23 weeks)
description: CR was determined by IRC at PRA according to the MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts). Values have been rounded off to the nearest whole number.
measure: Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by Investigator
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the investigator based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
measure: Arm G (Phase II NF Cohort): Percentage of Participants With OR at PRA Based on CT Only as Determined by IRC
time frame: 6 to 8 weeks after Cycle 6 Day 1 (cycle length is 21 days for DLBCL cohorts) or last dose of study drug (up to 23 weeks)
description: OR at PRA was defined as the percentage of participants with CR or PR at the PRA, as assessed by the IRC based on MLRC. Per MLRC, CR based on CT was defined as complete radiologic response in lymph nodes and ELS with target nodes/nodal masses regressing to ≤ 1.5 cm in LDi and no ELS of disease organ enlargement regressing to normal; no new lesions; normal bone marrow by morphology, if indeterminate, IHC negative. PR per CT only was defined as partial remission in lymph nodes and ELS with ≥50% decrease in SPD of up to 6 target measurable lymph nodes and extranodal sites, absent/normal/regressed but with no increase in non-measured lesions, spleen regressing by ≥50% in length beyond normal it, no new sites of lesions. The analysis was done 6-8 weeks after Cycle 6, Day 1 (each cycle is 21 days for DLBCL cohorts).
measure: Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
time frame: Cycle 1 Day 2: pre-dose and 30 minutes (min) post dose; Cycle 1 Days 8 and 15; Cycle 2 and 4 Day 1: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
description: PK of pola-related analyte acMMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
measure: Arm G+H (Phase II NF Cohorts): Plasma Concentration of of Polatuzumab Vedotin Analyte: acMMAE
time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
description: PK of one pola-related analytes: acMMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
measure: Serum Concentration of of Polatuzumab Vedotin Analyte: Total Ab
time frame: Cycle 1 Days 2: pre-dose & 30 min post dose; Cycle 1 Days 8 & 15; Cycle 2 and 4 Day 1 and unscheduled visits: pre-dose & 30 min post dose; Follow up at Day 1: Months 3, 6, 12, 18 & 24; study treatment completion visit (up to approx. 84 months)
description: PK of pola-related analyte Total Ab was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
measure: Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Total Ab
time frame: Cycle 1 Day 2: post dose; Cycle 2 and 4 Day 1: pre-dose and post dose
description: PK of pola-related analyte: Total Ab was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
measure: Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
time frame: Cycle 1 Day 2: pre-dose and 30 min post dose, Cycle 1 Days 8 and 15; Cycles 2 and 4: pre-dose and 30 min post dose; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
description: PK of pola-related analytes unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
measure: Arm G+H (Phase II NF Cohorts): Plasma Concentration of Polatuzumab Vedotin Analyte: Unconjugated MMAE
time frame: Cycle 1 Day 2: post dose; Cycle 1 and 3 Day 8 and 15; Cycle 2, 3 and 4 Day 1: pre-dose and post dose
description: PK of one pola-related analytes: Unconjugated MMAE was measured. Cycle length is 21 days for DLBCL cohorts. As pre-specified in the protocol data is reported combined for arms G+H.
measure: Plasma Concentration of Bendamustine
time frame: Cycle 1 Day 2: pre-dose, 5 min, 1 hour (h); 2h, 3h and 4h post dose
description: Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol plasma concentration of bendamustine was not assessed in the Phase II NF Cohort (Arm G+H).
measure: Serum Concentration of Rituximab
time frame: Cycle 1 Days 1: pre-dose and 30 min post dose; Cycle 2 and 4 Day 1: pre-dose; unscheduled visits: pre-dose and 30 min post dose (up to approximately 84 months)
description: Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts. As pre specified in the protocol serum concentration of rituximab was not assessed in the Phase II NF Cohort (Arm G+H).
measure: Serum Concentration of Obinutuzumab
time frame: Cycles 1 and 4 Days 1: pre-dose and 30 min post dose; Cycle 2 Day1: pre-dose; Follow up visits on Day 1: Months 3, 6, 12, 18 and 24; unscheduled visits: pre-dose and 30 min post dose; study treatment completion (up to approximately 84 months)
description: Cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts.
measure: Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: Cmax of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
time frame: Cycles 1, 2 and 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: Cmax of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody and unconjugated MMAE were measured.
measure: Phase II: Cmax of Bendamustine and Rituximab in Arms B and D
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
measure: Phase II: Cmax of Polatuzumab Vedotin, Obinutuzumab and Bendamustine in Arms E and F
time frame: Cycle 1; Cycle 4 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, unconjugated MMAE and total antibody were measured.
measure: Arm H (Phase II NF Cohort): Cmax of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4,(cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: AUC From Time Zero to Infinity (AUCinf) of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured. The unit of measure for AUC is day*micrograms per milliliter [day*ug/mL]).
measure: Phase Ib: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Rituximab in Arms A and C
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: AUCinf of Bendamustine and Rituximab in Arms B and D
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
measure: Phase II: AUCinf of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Arms E and F
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Arm H (Phase II NF Cohort): AUC of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (each cycle is 21 days DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: antibody acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Rituximab in Cohort 1a
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: CL of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: CL of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: CL of Bendamustine and Rituximab in Arms B and D
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
measure: Phase II: CL of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Arm H (Phase II NF Cohort): CL of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1a
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase Ib: Vss of Polatuzumab Vedotin, Bendamustine, and Obinutuzumab in Cohort 1b
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Rituximab in Arms A and C
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Phase II: Vss of Bendamustine and Rituximab in Arms B and D
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
measure: Phase II: Vss of Polatuzumab Vedotin, Bendamustine and Obinutuzumab in Arms E and F
time frame: Cycle 1 Day 2 (cycle length is 21 days for DLBCL cohorts and 28 days for FL cohorts)
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Arm H (Phase II NF Cohort): Vss of Polatuzumab Vedotin (Lyophilized)
time frame: Days 2, 8 and 15 of Cycle 1, Day 1 of Cycle 2 and 4, Day (cycle length is 21 days for DLBCL cohorts) up to approximately 9 weeks
description: PK of three pola-related analytes: acMMAE, total antibody, and unconjugated MMAE were measured.
measure: Symptom Severity and Interference According to Therapy-Induced Neuropathy Assessment Score (TINAS) in Arms A-F
time frame: Every week during treatment (up to 24 weeks) and for the first 2 months after treatment, thereafter every month for 10 months or until withdrawal (up to 18 months overall)
description: The TINAS is an 11-item questionnaire that assesses the severity of neuropathy-related symptoms in the last 24 hours. The 11 items assessed were: hot/burning sensations in hands/feet, sensations pins and needles arms/legs, numbness or tingling in hands/feet, sensations of electric shock, pain when touching cold things, cramps in hands/feet, discomfort when touching things, discomfort skin contact with something, trouble grasping small objects, trouble walking loss feeling legs/feet, difficulty balance loss feeling leg/feet. Each item was scored on a 0-10 scale, with 0 being the symptom is not present, and 10 being the symptom is as bad as the participant can imagine. Higher scores indicate more severe disease. Scores were averaged at each week.
arm group label: Arm A (Phase II Randomization): Polatuzumab+BR in FL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
arm group label: Arm B (Phase II Randomization): BR in FL
arm group type: Active Comparator
description: Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with FL.
arm group label: Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
arm group label: Arm D (Phase II Randomization): BR in DLBCL
arm group type: Active Comparator
description: Bendamustine and rituximab will be administered alone (that is, without polatuzumab vedotin) as a control arm in participants with DLBCL.
arm group label: Arm E (Phase II Expansion): Polatuzumab+BG in FL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
arm group label: Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with DLBCL.
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and rituximab in participants with FL.
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with DLBCL.
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL
arm group type: Experimental
description: Polatuzumab vedotin will be administered with bendamustine and obinutuzumab in participants with FL.
arm group label: Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group type: Experimental
description: In this New Formulation (NF) cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
arm group label: Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group type: Experimental
description: In this NF cohort, Polatuzumab vedotin (lyophilized) will be administered with bendamustine and rituximab in participants with DLBCL.
intervention type: Drug
intervention name: Bendamustine
description: Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
arm group label: Arm A (Phase II Randomization): Polatuzumab+BR in FL
arm group label: Arm B (Phase II Randomization): BR in FL
arm group label: Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL
arm group label: Arm D (Phase II Randomization): BR in DLBCL
arm group label: Arm E (Phase II Expansion): Polatuzumab+BG in FL
arm group label: Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL
arm group label: Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group label: Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL
other name: Treanda; Ribomustin; Levact
intervention type: Drug
intervention name: Obinutuzumab
description: Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
arm group label: Arm E (Phase II Expansion): Polatuzumab+BG in FL
arm group label: Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL
other name: GA101; Gazyva; Gazyvaro
intervention type: Drug
intervention name: Polatuzumab vedotin (Liquid)
description: Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
arm group label: Arm A (Phase II Randomization): Polatuzumab+BR in FL
arm group label: Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL
arm group label: Arm E (Phase II Expansion): Polatuzumab+BG in FL
arm group label: Arm F (Phase II Expansion): Polatuzumab+BG in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in DLBCL
arm group label: Cohort 1B (Phase Ib Safety Run-In): Polatuzumab+BG in FL
other name: DCDS4501A
intervention type: Drug
intervention name: Rituximab
description: Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
arm group label: Arm A (Phase II Randomization): Polatuzumab+BR in FL
arm group label: Arm B (Phase II Randomization): BR in FL
arm group label: Arm C (Phase II Randomization): Polatuzumab+BR in DLBCL
arm group label: Arm D (Phase II Randomization): BR in DLBCL
arm group label: Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group label: Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in DLBCL
arm group label: Cohort 1A (Phase Ib Safety Run-In): Polatuzumab+BR in FL
other name: Rituxan; MabThera
intervention type: Drug
intervention name: Polatuzumab vedotin (Lyophilized)
description: Participants in the New Formulation (NF) Cohort (Arms G and H) will follow the same schedule and dosing requirements as participants in the other Phase II cohorts (Arms A-F).
arm group label: Arm G (Phase II NF Cohort): Polatuzumab+BR in DLBCL
arm group label: Arm H (Phase II NF Cohort): Polatuzumab+BR in DLBCL
other name: DCDS4501S
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Clinical Trials
role: Study Director
affiliation: Hoffmann-La Roche
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
facility: 
country: Australia
country: Canada
country: Czechia
country: France
country: Germany
country: Hungary
country: Italy
country: Korea, Republic of
country: Netherlands
country: Spain
country: Turkey
country: United Kingdom
country: United States
country: Czech Republic
responsible party type: Sponsor
mesh term: Lymphoma
mesh term: Lymphoma, Large B-Cell, Diffuse
mesh term: Rituximab
mesh term: Obinutuzumab
mesh term: Bendamustine Hydrochloride
mesh term: Antibodies, Monoclonal
mesh term: Polatuzumab vedotin
mesh term: Immunoconjugates
provided document: 
participant flow: 
baseline: 
outcome list: 
reported events: 
certain agreements: 
point of contact: 